false 0001816708 2024 Q2 12/31 0.071 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure owlt:claim owlt:segment 0001816708 2024-01-01 2024-06-30 0001816708 2024-08-12 0001816708 2024-06-30 0001816708 2023-12-31 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2024-06-30 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2023-12-31 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2024-06-30 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2023-12-31 0001816708 2024-04-01 2024-06-30 0001816708 2023-04-01 2023-06-30 0001816708 2023-01-01 2023-06-30 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2022-12-31 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2022-12-31 0001816708 us-gaap:CommonStockMember 2022-12-31 0001816708 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001816708 us-gaap:RetainedEarningsMember 2022-12-31 0001816708 2022-12-31 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2023-01-01 2023-03-31 0001816708 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001816708 2023-01-01 2023-03-31 0001816708 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001816708 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2023-03-31 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2023-03-31 0001816708 us-gaap:CommonStockMember 2023-03-31 0001816708 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001816708 us-gaap:RetainedEarningsMember 2023-03-31 0001816708 2023-03-31 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2023-04-01 2023-06-30 0001816708 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001816708 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001816708 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2023-06-30 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2023-06-30 0001816708 us-gaap:CommonStockMember 2023-06-30 0001816708 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001816708 us-gaap:RetainedEarningsMember 2023-06-30 0001816708 2023-06-30 0001816708 us-gaap:CommonStockMember 2023-12-31 0001816708 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001816708 us-gaap:RetainedEarningsMember 2023-12-31 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2024-01-01 2024-03-31 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2024-01-01 2024-03-31 0001816708 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001816708 2024-01-01 2024-03-31 0001816708 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001816708 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2024-03-31 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2024-03-31 0001816708 us-gaap:CommonStockMember 2024-03-31 0001816708 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001816708 us-gaap:RetainedEarningsMember 2024-03-31 0001816708 2024-03-31 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2024-04-01 2024-06-30 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2024-04-01 2024-06-30 0001816708 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001816708 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001816708 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001816708 us-gaap:CommonStockMember 2024-06-30 0001816708 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001816708 us-gaap:RetainedEarningsMember 2024-06-30 0001816708 2023-07-06 0001816708 2023-07-07 0001816708 us-gaap:CommonStockMember 2023-07-07 0001816708 us-gaap:ConvertiblePreferredStockMember 2023-07-06 0001816708 us-gaap:ConvertiblePreferredStockMember 2023-07-07 0001816708 2023-02-17 2023-02-17 0001816708 2024-02-29 2024-02-29 0001816708 2023-07-07 2023-07-07 0001816708 owlt:ToolingAndManufacturingEquipmentMember 2024-06-30 0001816708 owlt:ToolingAndManufacturingEquipmentMember 2023-12-31 0001816708 us-gaap:FurnitureAndFixturesMember 2024-06-30 0001816708 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001816708 us-gaap:ComputerEquipmentMember 2024-06-30 0001816708 us-gaap:ComputerEquipmentMember 2023-12-31 0001816708 us-gaap:SoftwareDevelopmentMember 2024-06-30 0001816708 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001816708 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001816708 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001816708 us-gaap:PropertyPlantAndEquipmentMember 2024-04-01 2024-06-30 0001816708 us-gaap:PropertyPlantAndEquipmentMember 2023-04-01 2023-06-30 0001816708 owlt:ToolingAndManufacturingEquipmentMember 2024-04-01 2024-06-30 0001816708 owlt:ToolingAndManufacturingEquipmentMember 2023-04-01 2023-06-30 0001816708 us-gaap:PropertyPlantAndEquipmentMember 2024-01-01 2024-06-30 0001816708 us-gaap:PropertyPlantAndEquipmentMember 2023-01-01 2023-06-30 0001816708 owlt:ToolingAndManufacturingEquipmentMember 2024-01-01 2024-06-30 0001816708 owlt:ToolingAndManufacturingEquipmentMember 2023-01-01 2023-06-30 0001816708 us-gaap:ConvertiblePreferredStockMember 2024-06-30 0001816708 us-gaap:ConvertiblePreferredStockMember 2023-12-31 0001816708 srt:MinimumMember 2024-06-30 0001816708 srt:MaximumMember 2024-06-30 0001816708 owlt:TermNotePayableToSvbMember 2024-06-30 0001816708 owlt:TermNotePayableToSvbMember 2023-12-31 0001816708 owlt:TotalFinancedInsurancePremiumMember 2024-06-30 0001816708 owlt:TotalFinancedInsurancePremiumMember 2023-12-31 0001816708 owlt:SVBWarrantsMember 2023-03-31 0001816708 us-gaap:LineOfCreditMember 2024-06-30 0001816708 srt:MaximumMember us-gaap:LineOfCreditMember owlt:StreamlinePeriodInEffectMember 2024-06-30 0001816708 srt:MaximumMember us-gaap:LineOfCreditMember us-gaap:PrimeRateMember owlt:StreamlinePeriodInEffectMember 2024-06-30 0001816708 owlt:TermLoanMember 2022-11-23 0001816708 owlt:TermLoanMember 2024-06-30 0001816708 srt:MaximumMember us-gaap:LineOfCreditMember owlt:StreamlinePeriodNotInEffectMember 2024-06-30 0001816708 srt:MaximumMember us-gaap:LineOfCreditMember us-gaap:PrimeRateMember owlt:StreamlinePeriodNotInEffectMember 2024-06-30 0001816708 owlt:FinancedInsurancePremiumOneMember 2023-01-01 2023-12-31 0001816708 2023-02-28 0001816708 2021-11-01 2021-11-30 0001816708 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001816708 us-gaap:PerformanceSharesMember 2024-01-01 2024-06-30 0001816708 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001816708 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001816708 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001816708 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001816708 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001816708 us-gaap:SellingAndMarketingExpenseMember 2024-04-01 2024-06-30 0001816708 us-gaap:SellingAndMarketingExpenseMember 2023-04-01 2023-06-30 0001816708 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-06-30 0001816708 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-06-30 0001816708 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001816708 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001816708 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001816708 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001816708 us-gaap:SoftwareDevelopmentMember 2023-04-01 2023-06-30 0001816708 us-gaap:SoftwareDevelopmentMember 2024-04-01 2024-06-30 0001816708 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001816708 us-gaap:PerformanceSharesMember 2024-06-30 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2023-02-17 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2023-02-17 2023-02-17 0001816708 owlt:ConvertiblePreferredStockSeriesAMember 2024-01-01 2024-06-30 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2024-02-25 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2024-02-29 2024-02-29 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2024-02-25 2024-02-25 0001816708 owlt:ConvertiblePreferredStockSeriesBMember 2024-01-01 2024-06-30 0001816708 2024-02-25 2024-02-25 0001816708 owlt:PublicSharesMember us-gaap:IPOMember 2020-09-17 2020-09-17 0001816708 owlt:PublicWarrantMember us-gaap:IPOMember 2020-09-17 0001816708 owlt:PrivatePlacementWarrantMember 2020-09-17 0001816708 2020-09-17 2020-09-17 0001816708 owlt:SBGPublicWarrantsMember 2023-12-31 0001816708 owlt:SBGPublicWarrantsMember 2024-01-01 2024-06-30 0001816708 owlt:SBGPublicWarrantsMember 2024-06-30 0001816708 owlt:SBGPrivateWarrantsMember 2023-12-31 0001816708 owlt:SBGPrivateWarrantsMember 2024-01-01 2024-06-30 0001816708 owlt:SBGPrivateWarrantsMember 2024-06-30 0001816708 owlt:SeriesAWarrantsMember 2023-12-31 0001816708 owlt:SeriesAWarrantsMember 2024-01-01 2024-06-30 0001816708 owlt:SeriesAWarrantsMember 2024-06-30 0001816708 owlt:SeriesBWarrantsMember 2023-12-31 0001816708 owlt:SeriesBWarrantsMember 2024-01-01 2024-06-30 0001816708 owlt:SeriesBWarrantsMember 2024-06-30 0001816708 owlt:SVBWarrantsMember 2023-12-31 0001816708 owlt:SVBWarrantsMember 2024-01-01 2024-06-30 0001816708 owlt:SVBWarrantsMember 2024-06-30 0001816708 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-06-30 0001816708 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2024-06-30 0001816708 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2024-06-30 0001816708 us-gaap:MoneyMarketFundsMember 2024-06-30 0001816708 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001816708 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001816708 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001816708 owlt:SBGPublicWarrantsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001816708 owlt:SBGPublicWarrantsMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001816708 owlt:SBGPublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001816708 owlt:SBGPrivateWarrantsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001816708 owlt:SBGPrivateWarrantsMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001816708 owlt:SBGPrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001816708 owlt:SeriesAWarrantsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001816708 owlt:SeriesAWarrantsMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001816708 owlt:SeriesAWarrantsMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001816708 owlt:SeriesBWarrantsMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001816708 owlt:SeriesBWarrantsMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001816708 owlt:SeriesBWarrantsMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001816708 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001816708 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001816708 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2023-12-31 0001816708 us-gaap:MoneyMarketFundsMember 2023-12-31 0001816708 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001816708 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001816708 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001816708 owlt:SBGPublicWarrantsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001816708 owlt:SBGPublicWarrantsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001816708 owlt:SBGPublicWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001816708 owlt:SBGPrivateWarrantsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001816708 owlt:SBGPrivateWarrantsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001816708 owlt:SBGPrivateWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001816708 owlt:SeriesAWarrantsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001816708 owlt:SeriesAWarrantsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001816708 owlt:SeriesAWarrantsMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001816708 owlt:SBGPublicWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001816708 owlt:SBGPublicWarrantsMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001816708 owlt:SBGPublicWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001816708 owlt:SBGPublicWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001816708 owlt:SBGPublicWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001816708 owlt:SBGPublicWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001816708 owlt:SBGPublicWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001816708 owlt:SBGPublicWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001816708 owlt:SBGPublicWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001816708 owlt:SBGPublicWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001816708 owlt:SeriesAWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001816708 owlt:SeriesAWarrantsMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001816708 owlt:SeriesAWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001816708 owlt:SeriesAWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001816708 owlt:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001816708 owlt:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001816708 owlt:SeriesAWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001816708 owlt:SeriesAWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001816708 owlt:SeriesAWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001816708 owlt:SeriesAWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001816708 owlt:SeriesBWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-06-30 0001816708 owlt:SeriesBWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-02-29 0001816708 owlt:SeriesBWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-06-30 0001816708 owlt:SeriesBWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2024-02-29 0001816708 owlt:SeriesBWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001816708 owlt:SeriesBWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-02-29 0001816708 owlt:SeriesBWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001816708 owlt:SeriesBWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-02-29 0001816708 owlt:SeriesBWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001816708 owlt:SeriesBWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-02-29 0001816708 owlt:SVBWarrantsMember us-gaap:MeasurementInputSharePriceMember 2023-03-27 0001816708 owlt:SVBWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2023-03-27 0001816708 owlt:SVBWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2023-03-27 0001816708 owlt:SVBWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-27 0001816708 owlt:SVBWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-27 0001816708 us-gaap:ConvertiblePreferredStockMember 2024-04-01 2024-06-30 0001816708 us-gaap:ConvertiblePreferredStockMember 2023-04-01 2023-06-30 0001816708 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001816708 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001816708 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001816708 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001816708 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001816708 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001816708 us-gaap:PerformanceSharesMember 2024-01-01 2024-06-30 0001816708 us-gaap:PerformanceSharesMember 2023-01-01 2023-06-30 0001816708 us-gaap:EmployeeStockMember 2024-01-01 2024-06-30 0001816708 us-gaap:EmployeeStockMember 2023-01-01 2023-06-30 0001816708 owlt:CommonStockWarrantsMember 2024-01-01 2024-06-30 0001816708 owlt:CommonStockWarrantsMember 2023-01-01 2023-06-30 0001816708 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001816708 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001816708 country:US 2024-04-01 2024-06-30 0001816708 country:US 2023-04-01 2023-06-30 0001816708 country:US 2024-01-01 2024-06-30 0001816708 country:US 2023-01-01 2023-06-30 0001816708 country:GB 2024-04-01 2024-06-30 0001816708 country:GB 2023-04-01 2023-06-30 0001816708 country:GB 2024-01-01 2024-06-30 0001816708 country:GB 2023-01-01 2023-06-30 0001816708 us-gaap:NonUsMember 2024-04-01 2024-06-30 0001816708 us-gaap:NonUsMember 2023-04-01 2023-06-30 0001816708 us-gaap:NonUsMember 2024-01-01 2024-06-30 0001816708 us-gaap:NonUsMember 2023-01-01 2023-06-30 0001816708 country:US 2024-06-30 0001816708 country:US 2023-12-31 0001816708 us-gaap:NonUsMember 2024-06-30 0001816708 us-gaap:NonUsMember 2023-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________________________________________________________________
FORM 10-Q
____________________________________________________________________________
(Mark One)

x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____
Commission File Number: 001-39516
_____________________________________________
OWLET, INC.
(Exact Name of Registrant as Specified in its Charter)
_____________________________________________

Delaware | 85-1615012
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)
3300 North Ashton Boulevard, Suite 300 Lehi, Utah | 84043
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (844) 334-5330
_____________________________________________
Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share |  | OWLT |  | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | o | Accelerated filer | o
Non-accelerated filer | x | Smaller reporting company | x
Emerging growth company | x |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of August 12, 2024, the registrant had 9,412,953 shares of common stock, $0.0001 par value per share, outstanding.

2

Table of Contents

|  | Page
PART I. |  |
| Cautionary Note Regarding Forward-Looking Statements | 1
Item 1. | Financial Statements | 3
| Condensed Consolidated Balance Sheets (Unaudited) | 3
| Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) | 4
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit (Unaudited) | 5
| Condensed Consolidated Statements of Cash Flows (Unaudited) | 7
| Notes to Condensed Consolidated Financial Statements (Unaudited) | 8
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 21
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 28
Item 4. | Controls and Procedures | 28
PART II. |  |
Item 1. | Legal Proceedings | 31
Item 1A. | Risk Factors | 31
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 34
Item 3. | Defaults Upon Senior Securities | 35
Item 4. | Mine Safety Disclosures | 35
Item 5. | Other Information | 35
Item 6. | Exhibits | 36
| Signatures | 37

3

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this “Report”) contains certain statements that are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements other than statements of historical facts contained in this Report, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Report and are subject to a number of risks, uncertainties and assumptions described under the sections in this Report and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Form 10-K") entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in this Report and our Form 10-K. These forward-looking statements are subject to numerous risks, including, without limitation, the following:
•We have a limited operating history.
•We have not been profitable to date, and operating losses could continue, which could materially and adversely affect our business, financial condition and results of operations, including our ability to continue as a going concern.
•We have experienced fluctuations in the growth of our business and anticipate this will continue. If we fail to manage our growth effectively, our business could be materially and adversely affected.
•If any governmental authority or notified body were to require marketing authorization or similar certification for any product that we sell for which we have not obtained such marketing authorization or certification, we could be subject to regulatory enforcement action and/or required to cease selling or recall the product pending receipt of marketing authorization or similar certification from such other governmental authority or notified body, which can be a lengthy and time-consuming process, harm financial results and have long-term negative effects on our operations.
•Our products rely on mobile applications to function and we rely on Apple’s App Store and the Google Play Store for distribution of our mobile applications.
•A substantial portion of our sales comes through a limited number of retailers.
•We are required to obtain and maintain marketing authorizations or certifications from the FDA, foreign regulatory authorities or notified bodies for medical device products in the U.S. or in foreign jurisdictions, which can be a lengthy and time-consuming process, and a failure to do so on a timely basis, or at all, could severely harm our business.
•We currently rely on a single manufacturer for the assembly of our Smart Sock and Dream Sock products and a single manufacturer for the assembly of our Owlet Cam. We will likely rely on single manufacturers for future products we may develop. If we encounter manufacturing problems or delays, we may be unable to promptly transition to alternative manufacturers and our ability to generate revenue will be limited.
•If we are unable to obtain key materials and components from sole or limited source suppliers, we will not be able to deliver our products to customers.
•Our success depends in part on our proprietary technology, and if we are unable to obtain, maintain or successfully enforce our intellectual property rights, the commercial value of our products and services will be adversely affected, our competitive position may be harmed and we may be unable to operate our business profitably.
•Our business and operations may suffer in the event of IT system failures, cyberattacks or deficiencies in our cybersecurity.
•We are involved, and may become involved in the future, in disputes and other legal or regulatory proceedings that, if adversely decided or settled, could materially and adversely affect our business, financial condition and results of operations.
•We face the risk of product liability claims and the amount of insurance coverage held now or in the future may not be adequate to cover all liabilities we might incur.
•Operations in international markets will expose us to additional business, political, regulatory, operational, financial and economic risks.
•Our success depends substantially on our reputation and brand.
•Some of our products and services are in development or have been recently introduced into the market and may not achieve market acceptance, which could limit our growth and adversely affect our business, financial condition and results of operations.
1

•We have identified material weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, which may result in material misstatements of our consolidated financial statements, cause us to fail to meet our periodic reporting obligations or cause our access to the capital markets to be impaired.
•Our failure to meet the NYSE’s continued listing requirements could result in a delisting of our common stock.
•We may need to raise additional capital in the future in order to execute our strategic plan, which may not be available on terms acceptable to us, or at all.
These risks and other important factors, including those discussed in this Report, may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in an evolving environment. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included elsewhere in this Report are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements included elsewhere in this Report. In addition, even if our results of operations, financial condition and liquidity, and events in the industry in which we operate, are consistent with the forward-looking statements included elsewhere in this Report, they may not be predictive of results or developments in future periods.
Any forward-looking statement that we make in this Report speaks only as of the date of such statement. Except as required by law, we do not undertake any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this Report. For all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Reform Act.
As used in this Report, unless otherwise stated or the context otherwise requires: “we,” “us,” “our,” “Owlet,” the “Company,” and similar references refer to Owlet, Inc. and its subsidiaries, “common stock” refers to our Class A common stock.
Basis of Presentation for Reverse Stock Split
On July 7, 2023, we effected a 1-for-14 reverse stock split (the “Reverse Stock Split”) of our issued and outstanding common stock, by the filing of our Second Amended and Restated Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware pursuant to the Delaware General Corporation Law. The Reverse Stock Split became effective at 5:00 p.m. Eastern Time on July 7, 2023. Our common stock began trading on the New York Stock Exchange on a split-adjusted basis on July 10, 2023. Where applicable, all information presented in this Report has been retrospectively adjusted to give effect to our 1-for-14 reverse split of our outstanding common stock and, unless otherwise indicated, all such amounts and corresponding conversion price and/or exercise price data set forth in this Report has been adjusted to give effect to such reverse stock split.
2

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Owlet, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(unaudited)

|  | June 30, 2024 |  | December 31, 2023
Assets |  |  |  |
Current assets: |  |  |  |
Cash and cash equivalents |  | $ | 15,363 |  |  | $ | 16,557 |
Accounts receivable, net of allowance for credit losses of $542 and $3,322, respectively |  | 16,895 |  |  | 13,973 |
Inventory |  | 8,101 |  |  | 6,493 |
Prepaid expenses and other current assets |  | 2,171 |  |  | 2,921 |
Total current assets |  | 42,530 |  |  | 39,944 |
Property and equipment, net |  | 193 |  |  | 377 |
Right of use assets, net |  | 217 |  |  | 937 |
Intangible assets, net |  | 2,224 |  |  | 2,210 |
Other assets |  | 731 |  |  | 655 |
Total assets |  | $ | 45,895 |  |  | $ | 44,123 |
Liabilities, Convertible Preferred Stock, and Stockholders’ Deficit |  |  |  |
Current liabilities: |  |  |  |
Accounts payable |  | $ | 17,510 |  |  | $ | 13,679 |
Accrued and other expenses |  | 11,550 |  |  | 15,051 |
Current portion of deferred revenues |  | 1,242 |  |  | 1,166 |
Line of credit |  | 9,738 |  | 9,250 |
Current portion of long-term and other debt |  | 2,110 |  | 5,944 |
Total current liabilities |  | 42,150 |  |  | 45,090 |
Common stock warrant liabilities |  | 24,429 |  |  | 27,781 |
Other long-term liabilities |  | 150 |  |  | 928 |
Total liabilities |  | 66,729 |  |  | 73,799 |
Commitments and contingencies (Note 5) |  |  |  |
Series A convertible preferred stock, $0.0001 par value, 27,200 and 28,628 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively |  | 9,839 |  |  | 7,855 |
Series B convertible preferred stock, $0.0001 par value; 9,250 and 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively |  | 2,756 |  |  | — |
Stockholders’ deficit: |  |  |  |
Common stock, $0.0001 par value, 107,142,857 shares authorized as of June 30, 2024 and December 31, 2023; 9,099,539 and 8,797,456 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively. |  | 1 |  |  | 1 |
Additional paid-in capital |  | 220,102 |  |  | 218,127 |
Accumulated deficit |  | (253,532) |  |  | (255,659) |
Total stockholders’ deficit |  | (33,429) |  |  | (37,531) |
Total liabilities, convertible preferred stock, and stockholders’ deficit |  | $ | 45,895 |  |  | $ | 44,123 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3

Owlet, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share amounts)
(unaudited)

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Revenues | $ | 20,699 |  |  | $ | 13,088 |  |  | $ | 35,449 |  |  | $ | 23,824 |
Cost of revenues | 10,447 |  |  | 7,855 |  |  | 18,650 |  |  | 14,438 |
Gross profit | 10,252 |  |  | 5,233 |  |  | 16,799 |  |  | 9,386 |
Operating expenses: |  |  |  |  |  |  |
General and administrative | 6,290 |  |  | 6,124 |  |  | 12,340 |  |  | 14,990 |
Sales and marketing | 3,852 |  |  | 3,078 |  |  | 7,748 |  |  | 6,431 |
Research and development | 2,354 |  |  | 2,745 |  |  | 4,701 |  |  | 5,635 |
Total operating expenses | 12,496 |  |  | 11,947 |  |  | 24,789 |  |  | 27,056 |
Operating loss | (2,244) |  |  | (6,714) |  |  | (7,990) |  |  | (17,670) |
Other income (expense): |  |  |  |  |  |  |
Interest income (expense), net | 20 |  |  | (52) |  |  | (141) |  |  | (2,864) |
Common stock warrant liability adjustment | 1,028 |  |  | (1,629) |  |  | 10,207 |  |  | 283 |
Other (expense) income, net | 71 |  |  | (67) |  |  | 73 |  |  | (78) |
Total other (expense) income, net | 1,119 |  |  | (1,748) |  |  | 10,139 |  |  | (2,659) |
Income (loss) before income tax provision | (1,125) |  |  | (8,462) |  |  | 2,149 |  |  | (20,329) |
Income tax provision | (22) |  |  | (5) |  |  | (22) |  |  | (5) |
Net income (loss) and comprehensive income (loss) | (1,147) |  |  | (8,467) |  |  | 2,127 |  |  | (20,334) |
Accretion on convertible preferred stock | (1,535) |  |  | (1,326) |  |  | (2,863) |  |  | (1,979) |
Net loss attributable to common stockholders | $ | (2,682) |  |  | $ | (9,793) |  |  | $ | (736) |  |  | $ | (22,313) |
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.30) |  |  | $ | (1.19) |  |  | $ | (0.08) |  |  | $ | (2.73) |
Weighted-average number of shares outstanding used to compute net loss per share attributable to common stockholders, basic and diluted | 8,867,399 |  |  | 8,213,247 |  |  | 8,803,729 |  |  | 8,162,102 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4

Owlet, Inc.
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit
(in thousands, except share and per share amounts)
(unaudited)

| Series A Convertible Preferred Stock |  | Series B Convertible Preferred Stock |  | Common Stock |  |  |  |  |  |
| Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Total Stockholders' Deficit
Balance as of December 31, 2022 | — |  |  | $ | — |  |  | — |  |  | $ | — |  |  | 8,242,009 |  |  | $ | 1 |  |  | $ | 212,122 |  |  | $ | (222,758) |  |  | $ | (10,635) |
Issuance of preferred stock | 30,000 |  | 3867 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Preferred stock issuance costs | — |  |  | (253) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Accretion on Series A convertible preferred stock | — |  |  | 653 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (653) |  |  | — |  |  | (653) |
Issuance of SVB Warrants (Note 4) | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 43 |  |  | — |  |  | 43 |
Issuance of common stock upon exercise of stock options | — |  |  | — |  |  | — |  |  | — |  |  | 18,054 |  |  | — |  |  | 55 |  |  | — |  |  | 55 |
Issuance of common stock for restricted stock units vesting | — |  |  | — |  |  | — |  |  | — |  |  | 115,257 |  |  | — |  |  | — |  |  | — |  |  | — |
Issuance of common stock for employee stock purchase plan | — |  |  | — |  |  | — |  |  | — |  |  | 15,104 |  |  | — |  |  | 101 |  |  | — |  |  | 101 |
Stock-based compensation | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 2,789 |  |  | — |  |  | 2,789 |
Net loss | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (11,867) |  |  | (11,867) |
Balance as of March 31, 2023 | 30,000 |  |  | $ | 4,267 |  |  | — |  |  | $ | — |  |  | 8,390,424 |  |  | $ | 1 |  |  | $ | 214,457 |  |  | $ | (234,625) |  |  | $ | (20,167) |
Accretion on convertible preferred stock | — |  |  | 1,326 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,326) |  |  | — |  |  | (1,326) |
Issuance of common stock for restricted stock units vesting | — |  |  | — |  |  | — |  |  | — |  |  | 51,259 |  | — |  |  | — |  |  | — |  |  | — |
Stock-based compensation | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 2,644 |  |  | — |  |  | 2,644 |
Net loss | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (8,467) |  |  | (8,467) |
Balance as of June 30, 2023 | 30,000 |  |  | $ | 5,593 |  |  | — |  |  | $ | — |  |  | 8,441,683 |  |  | $ | 1 |  |  | $ | 215,775 |  |  | $ | (243,092) |  |  | $ | (27,316) |

5

Owlet, Inc.
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit (Continued)
(in thousands, except share and per share amounts)
(unaudited)

| Series A Convertible Preferred Stock |  | Series B Convertible Preferred Stock |  | Common Stock |  |  |  |  |  |
| Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Total Stockholders' Deficit
Balance as of December 31, 2023 | 28,628 |  |  | $ | 7,855 |  |  | — |  |  | $ | — |  |  | 8,797,456 |  |  | $ | 1 |  |  | $ | 218,127 |  |  | $ | (255,659) |  |  | $ | (37,531) |
Issuance of preferred stock | — |  |  | — |  |  | 9,250 |  |  | 2,394 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Preferred stock issuance costs | — |  |  | — |  |  | — |  |  | (102) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Accretion on convertible preferred stock | — |  |  | 1,212 |  |  | — |  |  | 116 |  |  | — |  |  | — |  |  | (1,328) |  |  | — |  |  | (1,328) |
Conversion of preferred stock | (1,178) |  |  | (332) |  |  | — |  |  | — |  |  | 171,719 |  |  | — |  |  | 332 |  |  | — |  |  | 332 |
Issuance of common stock for restricted stock units vesting | — |  |  | — |  |  | — |  |  | — |  |  | 22,437 |  |  | — |  |  | — |  |  | — |  |  | — |
Issuance of common stock for employee stock purchase plan | — |  |  | — |  |  | — |  |  | — |  |  | 22,791 |  |  | — |  |  | 92 |  |  | — |  |  | 92 |
Stock-based compensation | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 2,227 |  |  | — |  |  | 2,227 |
Net income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 3,274 |  |  | 3,274 |
Balance as of March 31, 2024 | 27,450 |  |  | $ | 8,735 |  |  | 9,250 |  |  | $ | 2,408 |  |  | 9,014,403 |  |  | $ | 1 |  |  | $ | 219,450 |  |  | $ | (252,385) |  |  | $ | (32,934) |
Accretion on convertible preferred stock | — |  |  | 1,187 |  |  | — |  |  | 348 |  |  | — |  |  | — |  |  | (1,535) |  |  | — |  |  | (1,535) |
Conversion of preferred stock | (250) |  |  | (83) |  |  | — |  |  | — |  |  | 36,443 |  |  | — |  |  | 83 |  |  | — |  |  | 83 |
Issuance of common stock for restricted stock units vesting | — |  |  | — |  |  | — |  |  | — |  |  | 48,693 |  |  | — |  |  | — |  |  | — |  |  | — |
Stock-based compensation | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 2,104 |  |  | — |  |  | 2,104 |
Net loss | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (1,147) |  |  | (1,147) |
Balance as of June 30, 2024 | 27,200 |  |  | $ | 9,839 |  |  | 9,250 |  |  | $ | 2,756 |  |  | 9,099,539 |  |  | $ | 1 |  |  | $ | 220,102 |  |  | $ | (253,532) |  |  | $ | (33,429) |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6

Owlet, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

| Six Months Ended June 30,
| 2024 |  | 2023
Cash flows from operating activities |  |  |
Net income (loss) | $ | 2,127 |  |  | $ | (20,334) |
Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |
Depreciation and amortization | 213 |  |  | 530 |
Stock-based compensation | 4,331 |  |  | 5,433 |
Provision for credit losses | (384) |  |  | 55 |
Common stock warrant liability adjustment | (10,207) |  |  | (283) |
Amortization of right of use assets | 721 |  |  | 667 |
Other adjustments, net | 37 |  |  | 39 |
Changes in assets and liabilities: |  |  |
Accounts receivable | (2,538) |  |  | 2,925 |
Prepaid expenses and other assets | 674 |  |  | 4,103 |
Inventory | (1,608) |  |  | 6,222 |
Accounts payable and accrued and other expenses | 1,196 |  |  | (16,134) |
Lease liabilities | (955) |  |  | (1,335) |
Other, net | (281) |  |  | 1,355 |
Net cash used in operating activities | (6,674) |  |  | (16,757) |
Cash flows from investing activities |  |  |
Purchase of property and equipment | (3) |  |  | (6) |
Purchase of intangible assets | (118) |  |  | (13) |
Net cash used in investing activities | (121) |  |  | (19) |
Cash flows from financing activities |  |  |
Proceeds from issuance of preferred stock, net of $394 and $295 of paid transaction costs, respectively | 8,856 |  |  | 29,793 |
Proceeds from short-term borrowings | 54,181 |  |  | 52,531 |
Payments of short-term borrowings | (54,528) |  |  | (51,189) |
Proceeds from long-term borrowings | — |  |  | 500 |
Payments of long-term borrowings | (3,000) |  |  | (1,500) |
Other, net | 92 |  |  | 156 |
Net cash provided by financing activities | 5,601 |  |  | 30,291 |
Net change in cash and cash equivalents | (1,194) |  |  | 13,515 |
Cash and cash equivalents at beginning of period | 16,557 |  |  | 11,231 |
Cash and cash equivalents at end of period | $ | 15,363 |  |  | $ | 24,746 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7

Owlet, Inc.
Notes to Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts)
(unaudited)
Note 1. Basis of Presentation
As used in these financial statements, unless otherwise stated or the context otherwise requires: “we,” “us,” “our,” “Owlet,” the “Company,” and similar references refer to Owlet, Inc. and its subsidiaries, “common stock” refers to our Class A common stock.
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and applicable rules and regulations of the U.S. Securities and Exchange Commission (the "SEC") regarding interim financial reporting. The condensed consolidated balance sheet as of December 31, 2023, included herein, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures including certain notes required by U.S. GAAP on an annual reporting basis. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary for the fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods presented. All dollar amounts, except per share amounts, in the notes are presented in thousands, unless otherwise specified.
Certain prior year amounts have been reclassified to conform to the current period presentation.
Reverse Stock Split
On July 7, 2023, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect a one-for-14 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock and a reduction in the number of authorized shares of common stock and authorized but unissued shares of the Company’s preferred stock. The number of authorized shares of Common Stock was reduced from 1,000,000,000 shares to 107,142,857 shares, which reflects a reduction to 1.5 times the then current number of authorized shares of Common Stock, divided by the Reverse Stock Split ratio. The Reverse Stock Split also reduced the number of authorized shares of preferred stock from 100,000,000 shares to 10,741,071 shares, which reflects a reduction to 1.5 times the then current number of authorized but unissued shares of preferred stock, divided by the Reverse Stock Split ratio. The Reverse Stock Split became effective on July 7, 2023.
There was no net effect on total stockholders' equity, and the par value per share of our common stock remains unchanged at $0.0001 per share after the Reverse Stock Split. All references made to share or per share amounts in the accompanying condensed consolidated financial statements and applicable disclosures have been retroactively adjusted for all periods presented to reflect the applicable effects of the Reverse Stock Split and the reduction in the number of authorized shares of common stock and preferred stock effected by the Charter Amendment.
Risks and Uncertainties
In accordance with ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.
Since inception, the Company has experienced recurring operating losses and generated negative cash flows from operations, resulting in an accumulated deficit of $253,532 as of June 30, 2024. During the six months ended June 30, 2024 and 2023, we had negative cash flows from operations of $6,674 and $16,757, respectively. As of June 30, 2024, we had $15,363 of cash on hand.
Recurring operating losses, negative cash flows from operations since inception, and a low cash balance relative to current obligations raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis and accordingly, do not include any adjustments relating to the recoverability and classification of asset carrying amounts, or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.
As the Company continues to address these financial conditions, management has undertaken the following actions:
8

•As described further in Note 7, on February 17, 2023 the Company consummated a sale of preferred stock and warrants to purchase its common stock for aggregate gross proceeds of $30,000. On February 29, 2024, the Company consummated a sale of preferred stock and warrants to purchase its common stock for aggregate gross proceeds of $9,250.
•As described in Note 4, the Company has entered into amendments to its financing arrangement with SVB, which, among other revisions, (i) deferred certain payments of principal (ii) deferred the maturity of the revolving line of credit from April 22, 2024 to December 31, 2024, (iii) had SVB waive certain stated events of default, (iv) expanded the eligibility of inventory and accounts that the Company can borrow against, and (v) modified certain financial covenants required of the Company.
•During the year ended December 31, 2022, the Company undertook restructuring actions, which significantly reduced employee headcount and reduced operating spend. This included the reduction of consulting and outside services, the reduction of marketing programs, and the prioritization of and sequencing of research and development projects.
We have not generated sufficient cash flows from operations to satisfy our capital requirements. There can be no assurance that the Company will generate sufficient future cash flows from operations due to potential factors, including but not limited to inflation, recession, or reduced demand for the Company’s products. If revenues decrease from current levels, the Company may be unable to further reduce costs, or such reductions may limit our ability to pursue strategic initiatives and grow revenues in the future.
There can be no assurance that we will be able to obtain additional financing on terms acceptable to us, if at all. Failure to secure additional funding may require us to modify, delay or abandon some of our planned future development, or to otherwise enact further operating cost reductions, which could have a material adverse effect on our business, operating results, financial condition and ability to achieve our intended business objectives.
If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and our business, financial condition and results of operations could be materially adversely affected. We also could be required to seek funds through arrangements with partners or others that may require us to relinquish rights or jointly own some aspects of our technologies, products or services that we would otherwise pursue on our own.
The Company maintains its cash in bank deposit accounts which, at times, exceed federally insured limits. As of June 30, 2024, substantially all of the Company’s cash was held with Silicon Valley Bank and Citibank, and exceeded federally insured limits. On March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver. On March 12, 2023, the Secretary of the Treasury, the chair of the Federal Reserve Board and the chairman of the FDIC released a joint statement related to the FDIC’s resolution of the Silicon Valley Bank receivership, which provided that all depositors would have access to all their money starting March 13, 2023. As of the issuance date of these financial statements, all cash deposited by the Company with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company, has been accessible by the Company.
Recently Issued Accounting Guidance
In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. The expanded annual disclosures are effective for our year ending December 31, 2024, and the expanded interim disclosures are effective in 2025 and will be applied retrospectively to all prior periods presented. Early adoption is permitted. The Company is currently assessing the impact of the guidance on its consolidated financial statements and disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires, among other things, additional disclosures primarily related to the income tax rate reconciliation and income taxes paid. The expanded annual disclosures are effective for our year ending December 31, 2025. The Company is currently evaluating the impact that ASU 2023-09 will have on our consolidated financial statements and whether we will apply the standard prospectively or retrospectively.
9

Note 2. Certain Balance Sheet Accounts
Allowance for Credit Losses
The Company records its accounts receivable at sales value and maintains an allowance for its current estimate of expected credit losses. Provisions for expected credit losses are estimated based on historical experience, assessment of specific risk, review of outstanding invoices, and forecasts about the future. The Company establishes specific reserves for customers in an adverse financial condition and adjusts for its expectations of changes in conditions that may impact the collectability of outstanding receivable.
The following table summarizes the Company's allowance for credit losses for the three and six months ended June 30, 2024 and 2023:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Beginning balance | $ | 500 |  |  | $ | 2,948 |  |  | $ | 3,322 |  |  | $ | 3,013 |
Charges to expense | 4 |  |  | (28) |  |  | (384) |  |  | 55 |
Charges to revenue | 38 |  |  | 69 |  |  | 94 |  |  | 49 |
Write-offs | $ | — |  |  | $ | (91) |  |  | $ | (2,490) |  |  | $ | (219) |
Ending balance | $ | 542 |  |  | $ | 2,898 |  |  | $ | 542 |  |  | $ | 2,898 |

Write-offs for the six months ended June 30, 2024 related to a settlement agreement with a former retailer for past due receivables which had previously been charged to the provision for credit losses in a prior period. A benefit was recognized during the six months ended June 30, 2024, which represented a partial recovery of the past due receivables in connection with the settlement.
Inventory
Substantially all of the Company’s inventory consisted of finished goods as of June 30, 2024 and December 31, 2023.
Property and Equipment, net
Property and equipment consisted of the following as of:

| June 30, 2024 |  | December 31, 2023
Tooling and manufacturing equipment | $ | 2,633 |  |  | $ | 2,632 |
Furniture and fixtures | 609 |  |  | 639 |
Computer equipment | 335 |  |  | 348 |
Software | 106 |  |  | 106 |
Leasehold improvements | 35 |  |  | 35 |
Total property and equipment | 3,718 |  |  | 3,760 |
Less accumulated depreciation and amortization | (3,525) |  |  | (3,383) |
Property and equipment, net | $ | 193 |  |  | $ | 377 |

Depreciation and amortization expense on property and equipment was $90 and $225 for the three months ended June 30, 2024 and June 30, 2023, respectively. For the three months ended June 30, 2024 and June 30, 2023, the Company allocated $84 and $148, respectively, of depreciation and amortization expense related to tooling and manufacturing equipment and software to cost of revenues.
Depreciation and amortization expense on property and equipment was $184 and $500 for the six months ended June 30, 2024 and June 30, 2023, respectively. For the six months ended June 30, 2024 and June 30, 2023, the Company allocated $169 and $330, respectively, of depreciation and amortization expense related to tooling and manufacturing equipment and software to cost of revenues.
Intangible Assets Subject to Amortization
Intangible assets were $2,224, net of accumulated amortization of $310 as of June 30, 2024, and $2,210, net of accumulated amortization of $280, as of December 31, 2023.
10

Capitalized software development costs were $1,873 on June 30, 2024 and December 31, 2023. The Company’s internally developed software capitalized within intangible assets on the balance sheet is still in development and not ready for general release. As such, the Company has not recognized any amortization for the three or six months ended June 30, 2024 or 2023.
The Company did not recognize any impairment charges for intangible assets during the three or six months ended June 30, 2024 or 2023.
Accrued and Other Expenses
Accrued and other expenses, among other things, included accrued sales returns of $998 and $2,919 as of June 30, 2024 and December 31, 2023, respectively.
Changes in accrued warranty were as follows:

| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Accrued warranty, beginning of period | $ | 768 |  |  | $ | 592 |  |  | $ | 782 |  |  | $ | 712 |
Provision for warranties issued during the period | 260 |  |  | 81 |  |  | 437 |  |  | 116 |
Settlements of warranty claims during the period | (185) |  |  | (82) |  |  | (376) |  |  | (237) |
Accrued warranty, end of period | $ | 843 |  |  | $ | 591 |  |  | $ | 843 |  |  | $ | 591 |

Preferred Stock
The Company is authorized to issue up to 10,741,071 shares of $0.0001 par value preferred stock, of which 36,450 and 28,628 shares were outstanding as of June 30, 2024 and December 31, 2023, respectively. See Note 7 - Convertible Preferred Stock and Common Stock Warrants of this Report for more information.
Note 3. Deferred Revenues
Deferred revenues relate to performance obligations for which payments are received from customers prior to the satisfaction of the Company’s obligations to its customers. Deferred revenues primarily consist of amounts allocated to the mobile application, unspecified upgrade rights, and content, and are recognized over the service period of the performance obligations, which range from 5 to 27 months.
Changes in the total deferred revenues balance were as follows:

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Beginning balance | $ | 1,280 |  |  | $ | 1,257 |  |  | $ | 1,302 |  |  | $ | 1,386 |
Deferral of revenues | 716 |  |  | 480 |  |  | 1,237 |  |  | 820 |
Recognition of deferred revenues | (606) |  |  | (514) |  |  | (1,149) |  |  | (983) |
Ending balance | $ | 1,390 |  |  | $ | 1,223 |  |  | $ | 1,390 |  |  | $ | 1,223 |

The Company recognized $491 and $456 of revenue during the three months ended June 30, 2024 and 2023, respectively, that was included in the deferred revenue balance at the beginning of the respective period.
The Company recognized $802 and $797 of revenue during the six months ended June 30, 2024 and 2023, respectively, that was included in the deferred revenue balance at the beginning of the respective period. Revenue for the six months ended June 30, 2024 includes $330 relating to the correction of immaterial misstatements from previous periods.
Note 4. Long-Term Debt and Other Financing Arrangements
The following is a summary of the Company’s long-term and other indebtedness as of:
11

| June 30, 2024 |  | December 31, 2023
Term note payable to SVB, maturing on October 1, 2024 | $ | 2,000 |  |  | $ | 5,000 |
Financed insurance premium | 110 |  | 944
Total debt | 2,110 |  |  | 5,944 |
Less: current portion | (2,110) |  |  | (5,944) |
Total long-term debt, net | $ | — |  |  | $ | — |

Third Amended and Restated Loan and Security Agreement
On November 23, 2022, the Company entered into the Third Amended and Restated Loan and Security Agreement (the “November 2022 LSA”) with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company (“SVB”). The November 2022 LSA amended, restated and replaced in its entirety the prior Second Amended and Restated Loan and Security Agreement, dated April 22, 2020, and all prior amendments. On March 27, 2023, the Company entered into the first amendment to the November 2022 LSA with SVB (the “March 2023 Amendment”), which, among other revisions, (i) deferred certain payments of principal by the Company until September 1, 2023, (ii) had SVB waive certain stated events of default, (iii) expanded the eligibility of inventory and accounts that the Company can borrow against, and (iv) modified certain financial covenants required of the Company.
In connection with the March 2023 Amendment, the Company granted SVB a warrant to purchase 10,714 shares of the Company's common stock at a price of $5.32 per share, expiring on March 27, 2035 (the "SVB Warrants"). The warrant was valued at $43 and is classified as equity and included within additional paid-in capital on the condensed consolidated balance sheet. See Note 7, Convertible Preferred Stock and Common Stock Warrants for a summary of all common stock warrants currently outstanding.
On August 10, 2023, the Company entered into the second amendment to the November 2022 LSA with SVB (the “August 2023 Amendment”) that clarified the calculation of the financial covenants under the agreement.
On November 13, 2023, the Company entered into a waiver and third amendment to the November 2022 LSA with SVB (the "November 2023 Amendment") to, among other things, waive a covenant violation and to revise the adjusted EBITDA requirements for future periods.
On March 8, 2024, the Company entered into a waiver and fourth amendment to the November 2022 LSA (the "March 2024 Amendment" and together with the November 2022 LSA, the March 2023 Amendment, the August 2023 Amendment, and the November 2023 Amendment, the "LSA") with SVB, which, among other revisions, (i) deferred the maturity of the revolving line of credit (the "SVB Revolver") from April 22, 2024 to December 31, 2024, (ii) had SVB waive certain stated events of default, (iii) expanded the eligibility of inventory and accounts that the Company can borrow against, and (iv) modified certain financial covenants required of the Company.
On May 10, 2024, the Company entered into a waiver agreement with SVB to waive a covenant violation of the adjusted EBITDA covenant for the three months ended December 31, 2023.
As of June 30, 2024, the Company was in compliance with all applicable covenants under the LSA.
Line of Credit
The LSA provides for a $10,000 revolving line of credit (the “SVB Revolver”) as of June 30, 2024. The SVB Revolver is an asset-based lending facility subject to borrowing base availability, which is limited by specified percentages of eligible accounts receivable and eligible inventory. Borrowing base availability can be impacted based upon the period’s eligible accounts receivable and eligible inventory and may be significantly lower than the full $10,000 line of credit. As of June 30, 2024 the borrowing base availability was $9,738.
The SVB Revolver facility matures and terminates on December 31, 2024. As of June 30, 2024, the SVB Revolver bore interest on the outstanding principal amount at a floating rate per annum equal to the greater of (i) 5.00% and (ii) the prime rate plus the prime rate margin, which is 2.25% for advances on the SVB Revolver, as defined by the LSA. As of June 30, 2024 there was $9,738 of outstanding borrowings under the SVB Revolver.
Term Loan
The LSA also provided for an $8,500 term loan (the “Term Loan”), replacing the term loans made under the previous agreement, of which $2,000 was outstanding as of June 30, 2024. The Term Loan amortizes with equal monthly installments of $500 and matures on October 1, 2024 (the "Term Loan Maturity Date").
12

The Term Loan accrues interest on the outstanding principal amount at a floating rate per annum equal to the greater of (i) five and three-quarters percent (5.75%) and (ii) the prime rate plus the prime rate margin, which is 3.50% for the Term Loan (as defined in the LSA), and such interest is payable (a) monthly in arrears, (b) on each prepayment date and (c) on the Term Loan Maturity Date. All outstanding principal and accrued and unpaid interest and all other Term Loan-related outstanding obligations shall become due and payable in full on the Term Loan Maturity Date.
The Company believes that the fair value of the Term Loan approximates the recorded amount as of June 30, 2024 and December 31, 2023, as the interest rates on the long-term debt are variable and the rates are based on market interest rates (bank’s prime rate) after consideration of default and credit risk (using Level 2 inputs).
Financed Insurance Premiums
In 2023, the Company renewed its corporate directors & officers and employment liability policies and entered into several new short-term commercial premium finance agreements with First Insurance Funding totaling $1,421 to be paid within one year, accruing interest at a weighted average rate of 9.0%. As of June 30, 2024, the remaining principal balance on the combined financed insurance premiums was $110.
Future Aggregate Maturities
As of June 30, 2024, future aggregate maturities of the Term Note and Financed Insurance Premium payables were as follows:

Years Ending December 31, |  | Amount
2024 |  | 2,110 |
Total |  | $ | 2,110 |

Note 5. Commitments and Contingencies
During February 2023, the Company entered into an agreement with a significant vendor to pay $3,000 of interest over 36 months with respect to past due payables. The present value of the future payments was expensed and included within interest expense, net on the condensed consolidated statements of operations for the six months ended June 30, 2023.
Litigation
The Company is involved in legal proceedings from time to time arising in the normal course of business. While any outcome related to such legal proceedings cannot be predicted with certainty, the Company believes that the outcome of these proceedings will not have a material impact on the Company’s financial position, results of operations, or liquidity.
In November 2021, two putative class action complaints were filed against us in the U.S. District Court for the Central District of California, the first captioned Butala v. Owlet, Inc., Case No. 2:21-cv-09016, and the second captioned Cherian v. Owlet, Inc., Case No. 2:21-cv-09293. Both complaints alleged violations of the Securities Exchange Act of 1934 (“Exchange Act”) against the Company and certain of its officers and directors on behalf of a putative class of investors who: (a) purchased the Company’s common stock between March 31, 2021 and October 4, 2021 (“Section 10(b) Claims”); or (b) held common stock in SBG as of June 1, 2021, and were eligible to vote at SBG's special meeting held on July 14, 2021 (“Section 14(a) Claims”). Both complaints allege, among other things, that the Company and certain of its officers and directors made false and/or misleading statements and failed to disclose certain information regarding the FDA’s likely classification of the Owlet Smart Sock as a medical device requiring marketing authorization.
On September 8, 2023, the Court ruled that while the Butala and Cherian cases were consolidated, there would be two distinct and separate classes to represent the Section 10(b) Claims and Section 14(a) Claims, respectively, and appointed lead plaintiffs and lead counsel for each class. Amended complaints were filed for each class on November 21, 2023, and then further amended in consolidated filings on December 22, 2023. The Company intends to vigorously defend itself against these claims, and filed motions to dismiss the complaints on February 9, 2024 on behalf of itself and the named officers and directors. The plaintiffs filed oppositions to the motions to dismiss on March 24, 2024, and the Company filed replies in support of the motions to dismiss on May 10, 2024. On August 5, 2024, the Court denied Owlet’s and its officers’ motions to dismiss the Section 10(b) Claims and the Section 14(a) Claims. The Court has yet to enter a scheduling order for the case.
Indemnification
13

In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless, and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors’ and officers’ insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is immaterial.
Note 6. Stock-based Compensation
The Company has various stock compensation plans, which are more fully described in Part II, Item 8 "Financial Statements and Supplementary Data - Note 8 to the Consolidated Financial Statements - Share-based Compensation" in the 2023 Annual Report on Form 10-K.
Under the 2021 Incentive Award Plan, the Company has the ability to grant options, stock appreciation rights, restricted stock, restricted stock units (“RSU”), performance stock units (“PRSU”), dividend equivalents, or other stock or cash-based awards to employees, directors, or consultants. Option awards are generally granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Options, RSU, and PRSU awards generally vest over a period of four years.
Stock-based Compensation Expense
Total stock-based compensation was recognized as follows (in thousands):

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
General and administrative | $ | 1,234 |  |  | $ | 1,461 |  |  | $ | 2,517 |  |  | $ | 2,897 |
Sales and marketing | 367 |  |  | 476 |  | 711 |  |  | 968
Research and development | 503 |  |  | 707 |  | 1,103 |  |  | 1,568
Total stock-based compensation | $ | 2,104 |  |  | $ | 2,644 |  |  | $ | 4,331 |  |  | $ | 5,433 |

There was no stock-based compensation capitalized during the three or six months ended June 30, 2024 or 2023.
As of June 30, 2024, the Company had $482 of unrecognized stock-based compensation costs related to non-vested options that will be recognized over a weighted-average period of 0.5 years, $6,500 of unrecognized stock-based compensation costs related to unvested RSUs that will be recognized over a weighted-average period of 1.9 years, and $257 of unrecognized stock-based compensation costs related to unvested PRSUs that will be recognized over a weighted-average period of 1.5 years.
Note 7. Convertible Preferred Stock and Common Stock Warrants
February 2023 Offering
On February 17, 2023 the Company entered into private placement investment agreements with certain investors, pursuant to which the Company issued and sold to the investors (i) an aggregate of 30,000 shares of the Company’s Series A convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 7,871,712 shares of the Company’s common stock, par value $0.0001 per share, (“Series A Warrants”) for an aggregate purchase price of $30,000.
The Series A convertible preferred stock is convertible into common stock at the option of the holder at any time after February 17, 2023 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) senior to the common stock and all other classes or series of equity securities of the Company established after February 17, 2023, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (ii) on parity with each class or series of equity securities of the Company established after the February 17, 2023, the terms of which expressly provide that it ranks on parity with the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iii) junior to each class or series of equity securities of the Company established after February 17, 2023, the terms of which expressly provide that
14

it ranks senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. Except as otherwise provided in the certificate of designation relating to the Series A convertible preferred stock or as required by law, holders of shares of Series A convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of stockholders of the Company, and not as a separate class.
At any time from and after February 17, 2028, the holders of at least a majority of the then outstanding shares of Series A convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series A preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 145.7726 per share (the "Conversion Rate"), (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series A preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.
Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, the Company will be required to pay an amount per share of Series A convertible preferred stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series A convertible preferred stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series A convertible preferred stock.
Each of the Series A Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $4.66 per share, is immediately exercisable, and will expire on February 17, 2028. As the Series A Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $26,133. The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $3,867 allocated to the Series A convertible preferred stock. The Series A convertible stock will accrete to its redemption value, starting from the issuance date to the date at which the shares become redeemable on February 17, 2028. Accretion will be recorded as a deemed dividend. None of the Series A Warrants have been exercised as of June 30, 2024.
The Company incurred $1,963 of issuance costs related to the offering. Issuance costs allocated to the preferred stock of $253 were recorded as a reduction to the Series A convertible preferred stock. Issuance costs allocated to the liability classified warrants of $1,710 were recorded as an expense within general and administrative expenses.
February 2024 Offering
On February 25, 2024 we entered into a private placement investment agreement with certain investors, pursuant to which we issued and sold to the investors (i) an aggregate of 9,250 shares of the Company’s Series B convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 1,799,021 shares of our common stock, par value $0.0001 per share (the “Series B Warrants”), for an aggregate purchase price of $9,250.
The Series B convertible preferred stock is convertible into common stock at the option of the holder at any time after February 29, 2024 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) equal to the Company’s Series A convertible preferred stock, (ii) senior to the common stock and all other classes or series of equity securities of the Company established after February 29, 2024, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (iii) on parity with each class or series of equity securities of the Company established after the February 29, 2024, the terms of which expressly provide that it ranks on parity with the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iv) junior to each class or series of equity securities of the Company established after February 29, 2024, the terms of which expressly provide that it ranks senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. Except as otherwise provided in the certificate of designation relating to the Series B convertible preferred stock or as required by law, holders of shares of Series B convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of stockholders of the Company, and not as a separate class.
At any time from and after March 1, 2029, the holders of at least a majority of the then outstanding shares of Series B convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series B convertible preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 129.6596 per share, (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series B preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.
Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, the Company will be required to pay an amount per share of Series B convertible preferred stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series B convertible preferred stock as would
15

have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series B convertible preferred stock.
Each of the Series B Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $7.7125 per share, is immediately exercisable, and will expire on March 1, 2029. As the Series B Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $6,856. The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $2,394 allocated to the Series B convertible preferred stock. The Series B convertible stock will accrete to its redemption value, starting from the issuance date to the date at which the shares become redeemable on March 1, 2029. Accretion will be recorded as a deemed dividend. None of the Series B Warrants have been exercised as of June 30, 2024.
The Company incurred $394 of issuance costs related to the offering. Issuance costs allocated to the preferred stock of $102 were recorded as a reduction to the Series B convertible preferred stock. Issuance costs allocated to the liability classified warrants of $292 were recorded as an expense within general and administrative expenses.
SBG Common Stock Warrants
As a result of the merger completed with SBG on July 15, 2021 (the “Merger”), the Company continues to record liabilities for warrants issued by SBG prior to the Merger.
Pursuant to the SBG initial public offering, SBG sold warrants to purchase an aggregate of 821,428 shares of the Company’s common stock at a price of $161.00 per share (“SBG Public Warrants”). Following the closing of the Initial Public Offering on September 17, 2020, the Company completed the sale of warrants to purchase an aggregate of 471,428 shares of the Company’s common stock at a price of $161.00 per share in a private placement to Sandbridge Acquisition Holdings LLC (the “SBG Private Placement Warrants”). Together, the SBG Public Warrants and SBG Private Placement Warrants are referred to as the “SBG Common Stock Warrants.” The SBG Public Warrants became exercisable 12 months from the closing of the Initial Public Offering. The SBG Common Stock Warrants will expire five years after the completion of the Merger or earlier upon redemption or liquidation.
See Part II, Item 8 “Financial Statements and Supplementary Data - Note 3 to the Consolidated Financial Statements - Merger” in the 2022 Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) for more information.
The following table summarizes issuable shares of the Company’s common stock based on warrant activity for the six months ended June 30, 2024:

| As of December 31, 2023 |  | Shares Issuable by New Warrants |  | Shares Purchased by Exercise |  | As of June 30, 2024
SBG Public Warrants | 821,428 |  | — |  | — |  | 821,428
SBG Private Placement Warrants | 471,428 |  | — |  | — |  | 471,428
Series A Warrants | 7,871,712 |  | — |  | — |  | 7,871,712
Series B Warrants | — |  | 1,799,021 |  | — |  | 1,799,021
SVB Warrants (Note 4) | 10,714 |  | — |  | — |  | 10,714
Total | 9,175,282 |  | 1,799,021 |  | — |  | 10,974,303

Note 8. Fair Value Measurements
The following table presents information about the Company’s assets and liabilities measured and reported in the financial statements at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.
16

| June 30, 2024
| Level 1 |  | Level 2 |  | Level 3 |  | Balance
Assets: |  |  |  |  |  |  |
Money market funds | $ | 15,232 |  | $ | — |  | $ | — |  | $ | 15,232
Total assets | $ | 15,232 |  | $ | — |  | $ | — |  | $ | 15,232
Liabilities: |  |  |  |  |  |  |
SBG Public Warrants | $ | — |  |  | $ | — |  |  | $ | 18 |  |  | $ | 18 |
SBG Private Placement Warrants | — |  |  | — |  |  | 10 |  |  | 10 |
Series A Warrants | — |  | — |  | 19,986 |  | 19,986
Series B Warrants | — |  | — |  | 4,415 |  | 4,415
Total liabilities | $ | — |  | $ | — |  | $ | 24,429 |  | $ | 24,429
| December 31, 2023
| Level 1 |  | Level 2 |  | Level 3 |  | Balance
Assets: |  |  |  |  |  |  |
Money market funds | $ | 16,489 |  |  | $ | — |  |  | $ | — |  |  | $ | 16,489 |
Total assets | $ | 16,489 |  | $ | — |  | $ | — |  | $ | 16,489
Liabilities: |  |  |  |  |  |  |
SBG Public Warrants | $ | — |  |  | $ | — |  |  | $ | 61 |  |  | $ | 61 |
SBG Private Placement Warrants | — |  | — |  | 35 |  | 35
Series A Warrants | $ | — |  | $ | — |  | $ | 27,685 |  | $ | 27,685
Total liabilities | $ | — |  | $ | — |  | $ | 27,781 |  | $ | 27,781

Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices.
The SBG Public Warrants and SBG Private Placement Warrants as of June 30, 2024 and December 31, 2023 are presented in Level 3 of the fair value hierarchy. On June 15, 2023, the Company received notice from the New York Stock Exchange (the “NYSE”) that the NYSE had halted trading in the SBG Public Warrants due to the low trading price of those warrants. On June 16, 2023, the NYSE provided written notice to the Company and publicly announced that NYSE Regulation had determined to commence proceedings to delist the SBG Public Warrants and that such warrants were no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. As such, these instruments are no longer valued using quoted market prices and correspondingly, the SBG Private Placement Warrants can no longer be valued based on a quoted market price of the SBG Public Warrants. The Company measured the fair value of both the SBG Public Warrants and the SBG Private Placement Warrants as of June 30, 2024 and December 31, 2023 using the Black-Scholes option pricing model with the following assumptions:

SBG Common Stock Warrants - Black-Scholes Inputs | June 30, 2024 |  | December 31, 2023
OWLT stock price | $ | 4.12 |  |  | $ | 5.28 |
Exercise price of warrants | $ | 161.00 |  |  | $ | 161.00 |
Term in years | 2.04 |  | 2.54
Risk-free interest rate | 4.70 | % |  | 4.11 | %
Volatility | 90.00 | % |  | 85.00 | %

The Series A Warrants are presented as Level 3 measurements, relying on unobservable inputs reflecting the Company’s own assumptions. Level 3 measurements, which are not based on quoted prices in active markets, introduce a higher degree of subjectivity and may be more sensitive to fluctuations in stock price, volatility rates, and U.S. Treasury Bond rates.
The Company measured the fair value of the Series A Warrants as of June 30, 2024 and December 31, 2023, using the Black-Scholes option pricing model with the following assumptions:
17

Series A Warrants - Black-Scholes Inputs | June 30, 2024 |  | December 31, 2023
OWLT stock price | $ | 4.12 |  |  | $ | 5.28 |
Exercise price of warrants | $ | 4.66 |  |  | $ | 4.66 |
Term in years | 3.63 |  | 4.13
Risk-free interest rate | 4.46 | % |  | 3.91 | %
Volatility | 90.00 | % |  | 85.00 | %

The Series B Warrants are presented as Level 3 measurements, relying on unobservable inputs reflecting the Company’s own assumptions. Level 3 measurements, which are not based on quoted prices in active markets, introduce a higher degree of subjectivity and may be more sensitive to fluctuations in stock price, volatility rates, and U.S. Treasury Bond rates.
The Company measured the fair value of the Series B Warrants at issuance and again as of June 30, 2024, using the Black-Scholes option pricing model with the following assumptions:

Series B Warrants - Black-Scholes Inputs | June 30, 2024 |  | February 29, 2024
OWLT stock price | $ | 4.12 |  |  | $ | 5.68 |
Exercise price of warrants | $ | 7.71 |  |  | $ | 7.71 |
Term in years | 4.66 |  | 5.00
Risk-free interest rate | 4.36 | % |  | 4.26 | %
Volatility | 90.00 | % |  | 90.00 | %

The following table presents a reconciliation of the Company’s SBG Public Warrants, SBG Private Placement Warrants, Series A Warrants, and Series B Warrants (together, the “Level 3 Warrants”) measured at fair value on a recurring basis as of June 30, 2024:

| Level 3 Warrants
Balance as of December 31, 2023 | $ | 27,781 |
Issuance of Series B Warrants | 6,855 |
Change in fair value included within common stock warrant liability adjustment | (10,207) |
Balance as of June 30, 2024 | $ | 24,429 |

There were no transfers between Level 1 and Level 2 in the periods reported. The SBG Public Warrants and SBG Private Placement Warrants were transferred into Level 3 in 2023, as discussed above.
The Company measured the fair value of the SVB Warrants (see Note 4) at issuance as of March 27, 2023, using the Black-Scholes option pricing model with the following assumptions:

SVB Warrants - Black-Scholes Inputs | March 27, 2023
OWLT stock price | $ | 4.62 |
Exercise price of warrants | $ | 5.32 |
Term in years | 12.00
Risk-free interest rate | 3.60 | %
Volatility | 85.00 | %

18

Note 9. Net Income (Loss) Per Share Attributable to Common Stockholders
Basic and diluted net income (loss) per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. Under the two-class method, net income (loss) is attributed to common stockholders and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.
The Company considers its convertible preferred stock to be participating securities. Under the two-class method, the net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holders of the Company’s convertible preferred stock do not have a contractual obligation to share in the Company’s losses.
The following table presents the calculation of basic and diluted net income (loss) per share attributable to common stockholders (in thousands, except share and per share amounts):

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Numerator: |  |  |  |  |  |  |
Net income (loss) and comprehensive loss | $ | (1,147) |  |  | $ | (8,467) |  |  | $ | 2,127 |  |  | $ | (20,334) |
Accretion on convertible preferred stock | (1,535) |  |  | (1,326) |  |  | (2,863) |  |  | (1,979) |
Net loss attributable to common stockholders (1) | $ | (2,682) |  |  | $ | (9,793) |  |  | $ | (736) |  |  | $ | (22,313) |
Denominator: |  |  |  |  |  |  |
Weighted-average common shares used in computed net loss per share attributable to common stockholders basic and diluted | 8,867,399 |  | 8,213,247 |  | 8,803,729 |  | 8,162,102
Net loss per share attributable to common stockholders basic and diluted | $ | (0.30) |  |  | $ | (1.19) |  |  | $ | (0.08) |  |  | $ | (2.73) |

(1) For the three and six months ended June 30, 2024 and 2023, the Company did not allocate its net loss to participating convertible preferred stock as those shares are not obligated to share in the losses of the Company.
The following table summarizes the common stock equivalents of potentially dilutive outstanding securities excluded from the computation of diluted net income (loss) per share due to their anti-dilutive effect:

| As of June 30,
| 2024 |  | 2023
Stock options | 361,723 |  |  | 473,240 |
RSUs | 1,479,657 |  |  | 299,646 |
PRSUs | 71,428 |  |  | 79,803 |
ESPP shares committed | 36,534 |  |  | 28,721 |
Common stock warrants | 10,974,303 |  |  | 9,175,289 |
Convertible preferred stock | 5,164,359 |  |  | 4,373,178 |
Total | 18,088,004 |  |  | 14,429,877 |

The Company’s 200,536 unvested earnout shares, described in Part II, Item 8 "Financial Statements and Supplementary Data - Note 9 to the Consolidated Financial Statements - Convertible Preferred Stock, Warrants, and Earnout Shares" in the 2023 Form 10-K, were excluded from the calculation of basic and diluted per share calculations as the vesting conditions have not yet been met as of June 30, 2024.
Note 10. Segments
The Company operates as a single operating segment. The Company’s chief operating decision maker manages the Company’s operations on a consolidated basis for purposes of allocating resources, making operating decisions, and evaluating financial performance. Since the Company operates in one operating segment, all required financial segment information can be found in these consolidated financial statements.
19

Revenue by geographic area is based on the delivery address of the customer and is summarized as follows (in thousands):

| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
United States | $ | 15,893 |  |  | $ | 11,834 |  |  | $ | 28,794 |  |  | $ | 21,377 |
United Kingdom | 2,109 |  | 674 |  | 2,965 |  | 1,136
Other | 2,697 |  | 580 |  | 3,690 |  | 1,311
Total revenues | $ | 20,699 |  |  | $ | 13,088 |  |  | $ | 35,449 |  |  | $ | 23,824 |

Other than the United States and the United Kingdom, no individual country exceeded 10% of total revenues for the three or six months ended June 30, 2024 and June 30, 2023.
The Company’s long-lived assets are composed of property and equipment and right of use assets, net, and are summarized by geographic area as follows as of (in thousands):

| June 30, 2024 |  | December 31, 2023
United States | $ | 258 |  |  | $ | 998 |
International | 152 |  |  | 316 |
Total long-lived assets, net | $ | 410 |  |  | $ | 1,314 |

20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Report and in “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Form 10-K. Certain statements we make under this Item 2 constitute “forward-looking statements” under the Reform Act. See “Cautionary Note Regarding Forward-Looking Statements” before Part I of this Report. You should consider our forward-looking statements in light of the risks discussed in our unaudited condensed consolidated financial statements, related notes and other financial information appearing elsewhere in this Report, the “Risk Factors” section of our Form 10–K and this Report, and our other filings with the SEC.
Overview
Our mission is to empower parents with the right information at the right time, to give them more peace of mind and help them find more joy in the journey of parenting. Our digital parenting platform aims to give parents real-time data and insights to help parents feel calmer and more confident. We believe that every parent deserves peace of mind and the opportunity to feel their well-rested best. We also believe that every child deserves to live a long, happy, and healthy life, and we are working to develop products to help facilitate that belief.
Components of Operating Results
Revenues
We recognize revenue primarily from products and the associated mobile applications. Revenues are recognized when control of goods and services is transferred to customers in an amount that reflects the consideration expected to be received by us in exchange for those goods and services. Substantially all of the Company’s revenues were derived from product sales.
Cost of Revenues
Cost of revenues consists of product costs, including contract manufacturing, shipping and handling, depreciation and amortization relating to tooling and manufacturing equipment and software, warranty replacement, fulfillment costs, warehousing, hosting, and reserves for excess and obsolete inventory.
Operating Expenses
General and Administrative. General and administrative expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for finance and accounting, legal, human resources and administrative executives and employees; third-party legal, accounting, customer service, software, and other professional services; corporate travel and entertainment; depreciation and amortization of property and equipment; and facilities rent.
Sales and Marketing. Sales and marketing expenses consist primarily of salaries, commissions, benefits, stock-based compensation, and bonuses for sales and marketing employees and contractors; third-party marketing expenses such as social media and search engine marketing; email marketing and print marketing.
Research and Development. Research and development expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for employees and contractors engaged in the design, development, maintenance and testing of our products and platforms.
Other Income (Expense)
Interest Expense, Net. Interest expense consists of interest incurred on our outstanding borrowings, including interest incurred on past due payables with one of our vendors as described in Note 5, Commitments and Contingencies, to the condensed consolidated financial statements included elsewhere in this Report, and amortization of the associated deferred financing costs. Interest expense is presented net of interest income earned on our money market account.
Common Stock Warrant Liability Adjustment. Mark to market adjustment to recognize the change in fair value of common stock warrant liabilities in other income (expense).
Other Income (Expense), Net. Other income (expense), net includes our net gain (loss) on foreign exchange transactions.
Income Tax Provision. Income tax provision consists primarily of U.S. federal and state income taxes related to the tax jurisdictions in which we conduct business.
21

Results of Operations
The following table sets forth our results of operations for the periods indicated in millions (note that amounts within this Item 2 shown in millions may not sum due to rounding):

|  | For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
|  |  |  | 2024 |  | 2023 |  | 2024 |  | 2023
Revenues |  |  |  | $ | 20.7 |  |  | $ | 13.1 |  |  | $ | 35.4 |  |  | $ | 23.8 |
Cost of revenues |  |  |  | 10.4 |  |  | 7.9 |  |  | 18.7 |  |  | 14.4 |
Gross profit |  |  |  | 10.3 |  |  | 5.2 |  |  | 16.8 |  |  | 9.4 |
Operating expenses: |  |  |  |  |  |  |  |  |  |
General and administrative |  |  |  | 6.3 |  |  | 6.1 |  |  | 12.3 |  |  | 15.0 |
Sales and marketing |  |  |  | 3.9 |  |  | 3.1 |  |  | 7.7 |  |  | 6.4 |
Research and development |  |  |  | 2.4 |  |  | 2.7 |  |  | 4.7 |  |  | 5.6 |
Total operating expenses |  |  |  | 12.5 |  |  | 11.9 |  |  | 24.8 |  |  | 27.1 |
Operating loss |  |  |  | (2.2) |  |  | (6.7) |  |  | (8.0) |  |  | (17.7) |
Other income (expense): |  |  |  |  |  |  |  |  |  |
Interest expense, net |  |  |  | — |  |  | (0.1) |  |  | (0.1) |  |  | (2.9) |
Common stock warrant liability adjustment |  |  |  | 1.0 |  |  | (1.6) |  |  | 10.2 |  |  | 0.3 |
Other income (expense), net |  |  |  | 0.1 |  |  | (0.1) |  |  | 0.1 |  |  | (0.1) |
Total other income (expense), net |  |  |  | 1.1 |  |  | (1.7) |  |  | 10.1 |  |  | (2.7) |
Loss before income tax provision |  |  |  | (1.1) |  |  | (8.5) |  |  | 2.1 |  |  | (20.3) |
Income tax provision |  |  |  | 0.0 |  |  | 0.0 |  |  | 0.0 |  | — |  | 0.0 |
Net loss and comprehensive loss |  |  |  | (1.1) |  |  | (8.5) |  |  | 2.1 |  |  | (20.3) |
Accretion on convertible preferred stock |  |  |  | (1.5) |  |  | (1.3) |  |  | (2.9) |  |  | (2.0) |
Net loss attributable to common stockholders |  |  |  | $ | (2.7) |  |  | $ | (9.8) |  |  | $ | (0.7) |  |  | $ | (22.3) |

Revenues

| For the Three Months Ended June 30, |  | Change |  | For the Six Months Ended June 30, |  | Change
(dollars in millions) | 2024 |  | 2023 |  | $ |  | % |  | 2024 |  | 2023 |  | $ |  | %
Revenues | $ | 20.7 |  |  | $ | 13.1 |  |  | $ | 7.6 |  |  | 58.2 | % |  | $ | 35.4 |  |  | $ | 23.8 |  |  | $ | 11.6 |  |  | 48.8 | %

Revenues increased by $7.6 million, or 58.2%, from $13.1 million for the three months ended June 30, 2023 to $20.7 million for the three months ended June 30, 2024. The increase was primarily due to higher sales of Owlet Sock products, reflecting an increase in consumer demand across all sales channels as compared to the same period in the prior year.
Revenues increased by $11.6 million, or 48.8%, from $23.8 million for the six months ended June 30, 2023 to $35.4 million for the six months ended June 30, 2024. The increase was primarily due to higher sales of Owlet Sock products, reflecting an increase in consumer demand across all sales channels as compared to the same period in the prior year.
Cost of Revenues and Gross Profit
22

| For the Three Months Ended June 30, |  | Change |  | For the Six Months Ended June 30, |  | Change
(dollars in millions) | 2024 |  | 2023 |  | $ |  | % |  | 2024 |  | 2023 |  | $ |  | %
Cost of revenues | $ | 10.4 |  |  | $ | 7.9 |  |  | $ | 2.6 |  |  | 33.0 | % |  | $ | 18.7 |  |  | $ | 14.4 |  |  | $ | 4.2 |  |  | 29.2 | %
Gross profit | $ | 10.3 |  |  | $ | 5.2 |  |  | $ | 5.0 |  |  | 95.9 | % |  | $ | 16.8 |  |  | $ | 9.4 |  |  | $ | 7.4 |  |  | 79.0 | %
Gross margin | 49.5 | % |  | 40.0 | % |  |  |  |  |  | 47.4 | % |  | 39.4 | % |  |  |  |

Cost of revenues increased by $2.6 million, or 33.0%, from $7.9 million for the three months ended June 30, 2023 to $10.4 million for the three months ended June 30, 2024. The increase was primarily due to the increase in product sales. Gross margin increased from 40.0% for the three months ended June 30, 2023 to 49.5% for the three months ended June 30, 2024 primarily due to higher revenue and lower direct product and fulfillment costs.
Cost of revenues increased by $4.2 million, or 29.2%, from $14.4 million for the six months ended June 30, 2023 to $18.7 million for the six months ended June 30, 2024. The increase was primarily due to the increase in product sales. Gross margin increased from 39.4% for the six months ended June 30, 2023 to 47.4% for the six months ended June 30, 2024 primarily due to higher revenue and lower direct product and fulfillment costs.
General and Administrative

| For the Three Months Ended June 30, |  | Change |  | For the Six Months Ended June 30, |  | Change
(dollars in millions) | 2024 |  | 2023 |  | $ |  | % |  | 2024 |  | 2023 |  | $ |  | %
General and administrative | $ | 6.3 |  |  | $ | 6.1 |  |  | $ | 0.2 |  |  | 2.7 | % |  | $ | 12.3 |  |  | $ | 15.0 |  |  | $ | (2.7) |  |  | (17.7 | %)

General and administrative expense increased by $0.2 million, or 2.7%, from $6.1 million for the three months ended June 30, 2023 to $6.3 million for the three months ended June 30, 2024. The increase was driven primarily by higher spend on outside consulting services, partially offset by lower cost of corporate insurance due to more favorable rates as compared to the same period in the prior year.
General and administrative expense decreased by $2.7 million, or 17.7%, from $15.0 million for the six months ended June 30, 2023 to $12.3 million for the six months ended June 30, 2024. The decrease was driven primarily by lower spend on outside consulting services, including lower transactions costs, and lower cost of corporate insurance due to more favorable rates as compared to the same period in the prior year.
Sales and Marketing

| For the Three Months Ended June 30, |  | Change |  | For the Six Months Ended June 30, |  | Change
(dollars in millions) | 2024 |  | 2023 |  | $ |  | % |  | 2024 |  | 2023 |  | $ |  | %
Sales and marketing | $ | 3.9 |  |  | $ | 3.1 |  |  | $ | 0.8 |  |  | 25.1 | % |  | $ | 7.7 |  |  | $ | 6.4 |  |  | $ | 1.3 |  |  | 20.5 | %

Sales and marketing expense increased by $0.8 million, or 25.1%, from $3.1 million for the three months ended June 30, 2023 to $3.9 million for the three months ended June 30, 2024. The increase was driven by higher spend on digital advertising and retail marketing, as well as higher compensation expense due to increased sales and marketing headcount and sales commissions as compared to the same period in the prior year.
Sales and marketing expense increased by $1.3 million, or 20.5%, from $6.4 million for the six months ended June 30, 2023 to $7.7 million for the six months ended June 30, 2024. The increase was driven by higher spend on digital advertising and retail marketing, as well as higher compensation expense due to increased sales and marketing headcount and sales commissions as compared to the same period in the prior year.
Research and Development

| For the Three Months Ended June 30, |  | Change |  | For the Six Months Ended June 30, |  | Change
(dollars in millions) | 2024 |  | 2023 |  | $ |  | % |  | 2024 |  | 2023 |  | $ |  | %
Research and development | $ | 2.4 |  |  | $ | 2.7 |  |  | $ | (0.4) |  |  | (14.2 | %) |  | $ | 4.7 |  |  | $ | 5.6 |  |  | $ | (0.9) |  |  | (16.6 | %)

23

Research and development expense decreased by $0.4 million, or 14.2%, from $2.7 million for the three months ended June 30, 2023 to $2.4 million for the three months ended June 30, 2024. The decrease was primarily driven by lower compensation expense from reduced research and development headcount as a result of the restructuring actions initiated in 2022.
Research and development expense decreased by $0.9 million, or 16.6%, from $5.6 million for the six months ended June 30, 2023 to $4.7 million for the six months ended June 30, 2024. The decrease was primarily driven by lower compensation expense from reduced research and development headcount as a result of the restructuring actions initiated in 2022.
Other Income (Expense)

| For the Three Months Ended June 30, |  | Change |  | For the Six Months Ended June 30, |  | Change
(dollars in millions) | 2024 |  | 2023 |  | $ |  | % |  | 2024 |  | 2023 |  | $ |  | %
Interest expense, net | $ | — |  |  | $ | (0.1) |  |  | $ | (0.1) |  |  | 138.5 | % |  | $ | (0.1) |  |  | $ | (2.9) |  |  | $ | 2.7 |  |  | (95.1 | %)
Common stock warrant liability adjustment | $ | 1.0 |  |  | $ | (1.6) |  |  | $ | 2.7 |  |  | (163.1 | %) |  | $ | 10.2 |  |  | $ | 0.3 |  |  | $ | 9.9 |  |  | 3,506.7 | %
Other income, net | $ | 0.1 |  |  | $ | (0.1) |  |  | $ | 0.1 |  |  | (206.0 | %) |  | $ | 0.1 |  |  | $ | (0.1) |  |  | $ | 0.2 |  |  | (193.6 | %)

Interest expense was mostly flat for the three months ended June 30, 2024 as compared to the same period in the prior year.
For the three months ended June 30, 2024, we recognized a gain of $1.0 million as compared to a loss of $1.6 million for the same period in the prior year resulting from a decrease in the fair value of common stock warrants outstanding. Additionally, the gain recognized for the three months ended June 30, 2024 included the decrease in fair value of the newly issued Series B Warrants, which were not outstanding during the same period in the prior year.
Interest expense decreased by $2.7 million, from $2.9 million for the six months ended June 30, 2023 to $0.1 million for the six months ended June 30, 2024. As described in Note 5, Commitments and Contingencies, to the condensed consolidated financial statements included elsewhere in this Report, we entered into an agreement with a significant vendor to pay $3.0 million of interest over 36 months with respect to past due payables. The present value of the future payments was expensed and included within interest expense, net on the condensed consolidated statements of operations for the six months ended June 30, 2023.
For the six months ended June 30, 2024, we recognized a gain of $10.2 million as compared to a gain of $0.3 million for the same period in the prior year resulting from a larger decrease in the fair value of common stock warrants outstanding. Additionally, the gain recognized for the six months ended June 30, 2024 included the decrease in fair value of the newly issued Series B Warrants, which were not outstanding during the same period in the prior year.
Liquidity and Capital Resources
We have historically funded our operations primarily with proceeds from issuances of our convertible preferred stock, issuances of our common stock, borrowings under our loan facilities, issuances of convertible promissory notes, and sales of our products and services. As of June 30, 2024, we had cash and cash equivalents of $15.4 million.
February 2023 Offering
On February 17, 2023 the Company entered into private placement investment agreements with certain investors, pursuant to which the Company issued and sold to the investors (i) an aggregate of 30,000 shares of the Company’s Series A convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 7,871,712 shares of the Company’s common stock, par value $0.0001 per share, (“Series A Warrants”) for an aggregate purchase price of $30.0 million.
The Series A convertible preferred stock is convertible into common stock at the option of the holder at any time after February 17, 2023 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) senior to the common stock and all other classes or series of equity securities of the Company established after February 17, 2023, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (ii) on parity with each class or series of equity securities of the Company established after the February 17, 2023, the terms of which expressly provide that it ranks on parity with the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iii) junior to each class or series of equity securities of the Company established after February 17, 2023, the terms of which expressly provide that it ranks senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. Except as otherwise provided in the certificate of designation relating to the Series A convertible preferred stock or
24

as required by law, holders of shares of Series A convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of stockholders of the Company, and not as a separate class.
At any time from and after February 17, 2028, the holders of at least a majority of the then outstanding shares of Series A convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series A preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 145.7726 per share (the "Conversion Rate"), (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series A preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.
Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, we will be required to pay an amount per share of Series A convertible preferred stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series A convertible preferred stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series A convertible preferred stock.
Each of the Series A Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $4.66 per share, is immediately exercisable, and will expire on February 17, 2028. As the Series A Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $26.1 million. The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $3.9 million allocated to the Series A convertible preferred stock. The Series A convertible stock will accrete to its redemption value, starting from the issuance date to the date at which the shares become redeemable on February 17, 2028. Accretion will be recorded as a deemed dividend. None of the Series A Warrants had been exercised as of June 30, 2024.
The Company incurred $2.0 million of issuance costs related to the offering. Issuance costs allocated to the preferred stock of $0.3 million were recorded as a reduction to the Series A convertible preferred stock. Issuance costs allocated to the liability classified warrants of $1.7 million were recorded as an expense within general and administrative expenses.
February 2024 Offering
On February 25, 2024 we entered into a private placement investment agreement with certain investors, pursuant to which we issued and sold to the investors (i) an aggregate of 9,250 shares of the Company’s Series B convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 1,799,021 shares of our common stock, par value $0.0001 per share (the “Series B Warrants”), for an aggregate purchase price of $9.3 million.
The Series B convertible preferred stock is convertible into common stock at the option of the holder at any time after February 29, 2024 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) equal to the Company’s Series A convertible preferred stock, (ii) senior to the common stock and all other classes or series of equity securities of the Company established after February 29, 2024, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (iii) on parity with each class or series of equity securities of the Company established after the February 29, 2024, the terms of which expressly provide that it ranks on parity with the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iv) junior to each class or series of equity securities of the Company established after February 29, 2024, the terms of which expressly provide that it ranks senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. Except as otherwise provided in the certificate of designation relating to the Series B convertible preferred stock or as required by law, holders of shares of Series B convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of stockholders of the Company, and not as a separate class.
At any time from and after March 1, 2029, the holders of at least a majority of the then outstanding shares of Series B convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series B convertible preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 129.6596 per share, (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series B preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.
Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, we will be required to pay an amount per share of Series B convertible preferred stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series B convertible preferred stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the
25

aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series B convertible preferred stock.
Each of the Series B Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $7.7125 per share, is immediately exercisable, and will expire on March 1, 2029. As the Series B Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $6.9 million. The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $2.4 million allocated to the Series B convertible preferred stock. The Series B convertible stock will accrete to its redemption value, starting from the issuance date to the date at which the shares become redeemable on March 1, 2029. Accretion will be recorded as a deemed dividend. None of the Series B Warrants have been exercised as of June 30, 2024.
We incurred $0.4 million of issuance costs related to the offering. Issuance costs allocated to the preferred stock of $0.1 million were recorded as a reduction to the Series B convertible preferred stock. Issuance costs allocated to the liability classified warrants of $0.3 million were recorded as an expense within general and administrative expenses.
Funding Requirements
In accordance with ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements included elsewhere in this Report are issued.
Since inception, we have experienced recurring operating losses and generated negative cash flows from operations, resulting in an accumulated deficit of $253.5 million as of June 30, 2024. During the six months ended June 30, 2024 and 2023, we had negative cash flows from operations of $6.7 million and $16.8 million, respectively. As of June 30, 2024, we had $15.4 million of cash on hand.
Recurring operating losses, negative cash flows from operations since inception, and a low cash balance relative to current obligations raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the accompanying condensed consolidated financial statements included elsewhere in this Report are issued. The condensed consolidated financial statements included elsewhere in this Report have been prepared on a going concern basis and accordingly, do not include any adjustments relating to the recoverability and classification of asset carrying amounts, or the amount and classification of liabilities that might result should we be unable to continue as a going concern.
As we continue to address these financial conditions, management have undertaken the following actions:
•As described above, on February 17, 2023 we consummated a sale of preferred stock and warrants to purchase our common stock for aggregate gross proceeds of $30.0 million. On February 29, 2024, we consummated a sale of preferred stock and warrants to purchase our common stock for aggregate gross proceeds of $9.3 million.
•As described in Note 4, Long-Term Debt and Other Financing Arrangements, we have entered into amendments to our financing arrangement with SVB, which, among other revisions, (i) deferred certain payments of principal (ii) deferred the maturity of the revolving line of credit from April 22, 2024 to December 31, 2024, (iii) had SVB waive certain stated events of default, (iv) expanded the eligibility of inventory and accounts that the Company can borrow against, and (v) modified certain financial covenants required of the Company.
•During the year ended December 31, 2022, we undertook restructuring actions, which significantly reduced employee headcount and reduced operating spend. This included the reduction of consulting and outside services, the reduction of marketing programs, and the prioritization of and sequencing of research and development projects.
We have not generated sufficient cash flows from operations to satisfy our capital requirements. There can be no assurance that we will generate sufficient future cash flows from operations due to potential factors, including but not limited to inflation, recession, or reduced demand for our products. If revenues decrease from current levels, we may be unable to further reduce costs, or such reductions may limit our ability to pursue strategic initiatives and grow revenues in the future.
There can be no assurance that we will be able to obtain additional financing on terms acceptable to us, if at all. Failure to secure additional funding may require us to modify, delay or abandon some of our planned future development, or to otherwise enact further operating cost reductions, which could have a material adverse effect on our business, operating results, financial condition and ability to achieve our intended business objectives.
If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances
26

could be significantly limited, and our business, financial condition and results of operations could be materially adversely affected. We also could be required to seek funds through arrangements with partners or others that may require us to relinquish rights or jointly own some aspects of our technologies, products or services that we would otherwise pursue on our own.
Loan and Security Agreement with Silicon Valley Bank
On November 23, 2022, we entered into the Third Amended and Restated Loan and Security Agreement (the “November 2022 LSA”) with Silicon Valley Bank, now a division of First Citizens Bank and Trust Company ("SVB"). The November 2022 LSA amended, restated and replaced in its entirety the prior Second Amended and Restated Loan and Security Agreement, dated April 22, 2020, and all prior amendments. On March 27, 2023, we entered into the first amendment to the November 2022 LSA with SVB (the “March 2023 Amendment”), which, among certain other revisions, (i) deferred certain payments of principal by us until September 1, 2023, (ii) had SVB waive certain stated events of default, (iii) expanded the eligibility of inventory and accounts that we can borrow against, and (iv) modified certain financial covenants required of us.
On August 10, 2023, we entered into the second amendment to the November 2022 LSA with SVB (the “August 2023 Amendment”) that clarified the calculation of the financial covenants under the agreement.
On November 13, 2023, we entered into a waiver and third amendment to the November 2022 LSA with SVB (the "November 2023 Amendment") to, among other things, waive a covenant violation and to revise the adjusted EBITDA requirements for future periods.
On March 8, 2024, we entered into a waiver and fourth amendment to the November 2022 LSA (the "March 2024 Amendment" and together with the November 2022 LSA, the March 2023 Amendment, the August 2023 Amendment, and the November 2023 Amendment, the "LSA") with SVB, which, among other revisions, (i) deferred the maturity of the revolving line of credit (the "SVB Revolver") from April 22, 2024 to December 31, 2024, (ii) had SVB waive certain stated events of default, (iii) expanded the eligibility of inventory and accounts that we can borrow against, and (iv) modified certain financial covenants required of the Company.
On May 10, 2024, the Company entered into a waiver agreement with SVB to waive a covenant violation of the adjusted EBITDA covenant for the three months ended December 31, 2023.
As of June 30, 2024, the Company was in compliance with all applicable covenants under the LSA.
Line of Credit
The LSA provides for a $10.0 million revolving line of credit (the “SVB Revolver”) as of June 30, 2024. The SVB Revolver is an asset-based lending facility subject to borrowing base availability, which is limited by specified percentages of eligible accounts receivable and eligible inventory. Borrowing base availability can be impacted based upon the period's eligible accounts receivable and eligible inventory, and may be significantly lower than the full $10.0 million line of credit. As of June 30, 2024 the borrowing base availability was $9.7 million.
The SVB Revolver facility matures and terminates on December 31, 2024. As of June 30, 2024, the SVB Revolver bore interest on the outstanding principal amount at a floating rate per annum equal to the greater of (i) 5.00% and (ii) the prime rate plus the prime rate margin, which is 2.25% for advances on the SVB Revolver, as defined by the LSA.
Term Loan
The LSA also provided for an $8.5 million term loan (the “Term Loan”), replacing the term loans made under the previous agreement, of which $2.0 million was outstanding as of June 30, 2024. The Term Loan amortizes with equal monthly installments of $0.5 million and matures on October 1, 2024 (the "Term Loan Maturity Date").
The Term Loan accrues interest on the outstanding principal amount at a floating rate per annum equal to the greater of (i) five and three-quarters percent (5.75%) and (ii) the prime rate plus the prime rate margin, which is 3.50% for the Term Loan (as defined in the LSA), and such interest is payable (a) monthly in arrears, (b) on each prepayment date and (c) on the Term Loan Maturity Date. All outstanding principal and accrued and unpaid interest and all other Term Loan-related outstanding obligations shall become due and payable in full on the Term Loan Maturity Date.
We believe that the fair value of the Term Loan approximates the recorded amount as of June 30, 2024 and December 31, 2023, as the interest rates on the long-term debt are variable and the rates are based on market interest rates (bank's prime rate) after consideration of default and credit risk (using Level 2 inputs).
Financed Insurance Premium
In July 2023, we renewed our corporate directors & officers and employment liability policies and entered into a new short-term commercial premium finance agreement with First Insurance Funding totaling $1.4 million to be paid in eleven equal monthly
27

payments, accruing interest at a rate of 9.0%. As of June 30, 2024, the remaining principal balance on the combined financed insurance premiums was $0.1 million.
Cash Flows
The following table summarizes our cash flow (in millions):

| Six Months Ended June 30,
| 2024 |  | 2023
Net cash used in operating activities | $ | (6.7) |  |  | $ | (16.8) |
Net cash used in investing activities | (0.1) |  |  | — |
Net cash provided by financing activities | 5.6 |  |  | 30.3 |
Net change in cash and cash equivalents | $ | (1.2) |  |  | $ | 13.5 |

Operating Activities
For the six months ended June 30, 2024, net cash used in operating activities was $6.7 million as compared to net cash used in operating activities of $16.8 million in the prior year. The change in operating cash flows was primarily driven by a lower operating loss, which was $8.0 million for the six months ended June 30, 2024 as compared to an operating loss of $17.7 million for the same period in the prior year.
Investing Activities
For the six months ended June 30, 2024 and 2023, we used substantially no cash for investing activities, due to the prioritization of research and development projects in correlation with the restructuring actions taken during the fiscal year 2022.
Financing Activities
For the six months ended June 30, 2024 and 2023, net cash provided by financing activities was $5.6 million and $30.3 million, respectively. The decrease is primarily driven by the higher amount proceeds raised by the Series A preferred stock offering in February 2023 as compared to the proceeds raised by the Series B preferred stock offering in February 2024. Additionally, the Company made payments on the Term Loan totaling $3.0 million during the six months ended June 30, 2024, compared to payments totaling $1.5 million during the six months ended June 30, 2023.
Critical Accounting Policies and Estimates
There have been no material changes from the critical accounting policies and estimates disclosed in our Form 10-K, other than policies disclosed in this Report.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item.
Item 4. Controls and Procedures.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures (as such terms are defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
28

Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of June 30, 2024, the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of June 30, 2024 due to the material weaknesses in our internal control over financial reporting described below.
Material Weaknesses in Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13(a)-15(f) and 15(d)-15(f) under the Exchange Act.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. The following material weaknesses in our internal control over financial reporting exist as of June 30, 2024.
We did not design and maintain an effective control environment commensurate with our financial reporting requirements. Specifically, we did not maintain a sufficient complement of personnel with an appropriate degree of internal controls and accounting knowledge, experience, and training commensurate with our accounting and financial reporting requirements. This material weakness contributed to the following additional material weaknesses:
•We did not design and maintain effective controls over the segregation of duties related to journal entries. Specifically, certain personnel have the ability to both create and post journal entries within the Company’s general ledger system. This material weakness did not result in any adjustments to the consolidated financial statements.
•We did not design and maintain effective controls over the accounting for the accuracy and existence of inventory, nor controls which verified the completeness and accuracy of accrued liabilities. Each of these material weaknesses resulted in immaterial adjustments that were recorded as out-of-period adjustments within the year ended December 31, 2022.
•We did not design and maintain effective controls over the accounting for convertible preferred stock and warrant arrangements. Further, we did not design and maintain effective controls to verify the completeness and accuracy of sales returns and accrued sales tax. Each of these material weaknesses resulted in material adjustments to several account balances and disclosures in the consolidated financial statements as of and for the year ended December 31, 2019. The sales returns material weakness also resulted in immaterial adjustments to revenue and accrued and other expenses as of and for the year ended December 31, 2022.
•We did not design and maintain effective controls over IT general controls for information systems that are relevant to the preparation of our consolidated financial statements. Specifically, we did not design and maintain (i) program change management controls to ensure that IT program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately, (ii) user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial applications, programs, and data to appropriate Company personnel, (iii) computer operations controls to ensure that critical batch jobs are monitored, and data backups are authorized and monitored, and (iv) testing and approval controls for program development to ensure that new software development is aligned with business and IT requirements. This material weakness did not result in any adjustments to the consolidated financial statements.
Additionally, each of the material weaknesses described above could result in a misstatement of one or more account balances or disclosures that would result in a material misstatement to the interim or annual consolidated financial statements that would not be prevented or detected.
Remediation Plan
We have initiated a plan to remediate these material weaknesses. The remediation measures will be ongoing, and although not all inclusive, remediation measures include hiring additional accounting and financial reporting personnel and implementing additional policies, procedures and controls, all of which will result in future costs for the Company.
We have taken actions to improve our IT general controls, segregation of duties over journal entries controls, inventory controls, accrued liabilities, convertible preferred stock, warrant arrangements, sales returns and accrued sales tax controls. However, the material weaknesses will not be considered remediated until our remediation plan has been fully implemented, the applicable controls operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are operating effectively.
Notwithstanding the above, our management believes that the consolidated financial statements included in this Report on Form 10-Q state fairly in all material respects our financial position, results of operations and cash flows for the periods presented.
29

Changes in Internal Control over Financial Reporting
Other than the remediation efforts described above, there have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended June 30, 2024 that have materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
30

PART II
Item 1. Legal Proceedings.
From time to time, we may become involved in various legal proceedings that arise in the ordinary course of business. We evaluate any claims and lawsuits with respect to their potential merits, our potential defenses and counterclaims, and the expected effect on us of defending the claims and a potential adverse result. However, the results of any litigation, investigations or other legal proceedings are inherently unpredictable and expensive. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, damage to our reputation, and divert significant resources. If any legal proceedings were to be determined adversely to us, or we were to enter into a settlement agreement, we could be exposed to monetary damages or limits on our ability to operate our business, which could have an adverse effect on our business, financial condition and operating results. For a description of our legal proceedings, see Note 5 to our unaudited consolidated financial statements included elsewhere in this Report, which is incorporated herein by reference.
Item 1A. Risk Factors.
Our business, financial condition and operating results can be affected by a number of factors, including but not limited to those described as risk factors, any one or more of which could, directly or indirectly, cause our actual operating results and financial condition to vary materially from past, or anticipated future, operating results and financial condition. For a discussion of these potential risks and uncertainties, see Part I, Item 1A. "Risk Factors" in our Form 10-K, as supplemented by the risk factors below. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and the price of our common stock.
Risks Related to Our Business and Operations
If any governmental authority or notified body were to require marketing authorization or similar certification for any product that we sell for which we have not obtained such marketing authorization or certification, we could be subject to regulatory enforcement actions and/or be required to cease selling or recall the product pending receipt of marketing authorization or similar certification from such other governmental authority or notified body, which can be a lengthy and time-consuming process, harm financial results and have long-term negative effects on our operations.
We currently sell Smart Sock and Dream Sock in certain countries outside of the U.S., and we have not obtained medical device marketing authorizations, approvals, or certifications from any governmental authority or notified body, other than from the U.S. Food and Drug Administration ("FDA") for Dream Sock and BabySat and from the notified body BSI under European Union (“EU”) and United Kingdom (“UK”) EU Medical Devices Regulation (2017/745 or “MDR”) for Dream Sock. In response to inquiries from the FDA and regulatory authorities in other jurisdictions regarding the marketing of Smart Sock and Dream Sock (in the case of the FDA, prior to ceasing distribution of Smart Sock and prior to our recent marketing authorization for Dream Sock Health Notifications features), we had communicated our beliefs that such products are not medical devices that require medical device or similar marketing authorization or certification from such other regulatory authorities or notified bodies. However, certain regulatory authorities had expressed that they did not agree with that conclusion and in some instances required us to obtain marketing authorization, such as a clearance or approval, or other certification to continue to sell the product.
For example, Owlet has been corresponding with the Medical Devices Directorate, Canada's medical device regulatory authority within Health Canada, regarding the device classification requirements of Smart Sock and Dream Sock. As a result of these exchanges, Owlet ceased selling and advertising Smart Sock in Canada on December 10, 2021. We have, however, marketed and sold Dream Sock in Canada since January 2022. Health Canada, the regulatory authority responsible for the Canadian medical device market, initially asserted that Dream Sock was a medical device that can no longer be sold in Canada unless a relevant license has been issued. In the second half of 2022, we responded with our position that Dream Sock is not a medical device, and Health Canada has not affirmatively concluded that it agrees or disagrees with our position. If Health Canada does not agree with our position, we may be required to cease distribution of the product into the Canadian market and may be subject to enforcement action.
Obtaining and maintaining authorization or certification to sell any of our products as medical devices is a time-consuming and costly process and we may be precluded from selling such products if we are required to obtain marketing authorization, such as a clearance or approval, or other certification, and maintain such authorizations if received. The path to market varies among international jurisdictions and may require additional or different product testing than required to obtain FDA marketing authorization. Certifications or marketing authorizations from one foreign regulatory authority or notified body does not ensure certification or
31

marketing authorization by any other foreign regulatory authority or notified body or by the FDA. If we fail to receive necessary certifications or marketing authorizations to commercialize our products in any jurisdictions on a timely basis, or at all, or if we later lose such certifications or marketing authorizations, our business, financial condition and results of operations could be adversely affected. Furthermore, regulatory requirements may change from time to time, which could adversely affect our ability to market new products and services, or continue to market existing products and services. Moreover, even if granted, a marketing authorization or certification could require conditions to sale, such as a prescription requirement. If regulatory authorities require such marketing authorization, including clearance or approval, or other certifications for the products that we sell, we could be subject to regulatory enforcement action, time-consuming and costly marketing authorization and certification application processes, or required to cease selling or to recall the product in the corresponding jurisdiction pending receipt of such marketing authorization or certification. We also could be required to modify the product’s functionality or limit our marketing claims for the product, whether or not we obtain such marketing authorization or other required certification. In any such event, our business could be substantially harmed.
We are involved, and may become involved in the future, in disputes and other legal or regulatory proceedings that, if adversely decided or settled, could materially and adversely affect our business, financial condition and results of operations.
We are, and may in the future become, party to litigation, regulatory proceedings or other disputes. In general, claims made by or against us in disputes and other legal or regulatory proceedings can be expensive and time-consuming to bring or defend against, requiring us to expend significant resources and divert the efforts and attention of our management and other personnel from our business operations. These potential claims may include but are not limited to personal injury and class action lawsuits, intellectual property claims and regulatory investigations relating to the advertising and promotional claims about our products and services and employee claims against us based on, among other things, discrimination, harassment or wrongful termination. Any one of these claims, even those without merit, may divert our financial and management resources that would otherwise be used to benefit the future performance of our operations. Any adverse determination against us in these proceedings, or even the allegations contained in the claims, regardless of whether they are ultimately found to be without merit, may also result in settlements, injunctions or damages that could have a material adverse effect on our business, financial condition and results of operations.
Additionally, in the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. In November 2021, two putative class action complaints were filed against us in the U.S. District Court for the Central District of California. Both complaints alleged violations of the Exchange Act against the Company and certain of our officers and directors on behalf of a putative class of investors who: (a) purchased the Company’s common stock between March 31, 2021 and October 4, 2021 (“Section 10(b) Claims”); or (b) held common stock in SBG as of June 1, 2021, and were eligible to vote at SBG's special meeting held on July 14, 2021 (“Section 14(a) Claims”). Both complaints allege, among other things, that we and certain of our officers and directors made false and/or misleading statements and failed to disclose certain information regarding the FDA’s likely classification of the Owlet Smart Sock as a medical device requiring marketing authorization. On September 8, 2023, the Court ruled that while the two cases were consolidated, there would be two distinct and separate classes to represent the Section 10(b) Claims and Section 14(a) Claims, respectively, and appointed lead plaintiffs and lead counsel. An amended complaint was filed for both classes on November 21, 2023, and then further amended and consolidated filings by the plaintiffs’ counsel on December 22, 2023. The Company intends to vigorously defend itself against these claims and filed on February 9, 2024 motions to dismiss the cases in response to these complaints, on behalf of itself and the named officers and directors. The plaintiffs filed oppositions to the motions to dismiss on March 24, 2024, and the Company filed replies in support of the motions to dismiss on May 10, 2024. On August 5, 2024, the Court denied Owlet’s and its officers’ motions to dismiss the Section 10(b) Claims and the Section 14(a) Claims. The Court has yet to enter a scheduling order for the case. These lawsuits and any future lawsuits to which we may become a party are subject to inherent uncertainties and will likely be expensive and time-consuming to investigate, defend and resolve. Any litigation to which we are a party may result in an onerous or unfavorable judgment that may not be reversed upon appeal, or in payments of substantial monetary damages or fines, or we may decide to settle this or other lawsuits on similarly unfavorable terms, which could have a material adverse effect on our business, financial condition, results of operations or stock price.
Risks Related to Regulation of Our Industry and Products
Marketing authorization for our prescription-required BabySat pediatric monitor does not ensure commercial success of this product. Successful commercialization of this product will require us to implement processes, procedures and operations necessary to market and sell medical devices. We may not be successful in implementing these conditions, which could subject us to new risks.
In June 2023, we received our first medical device marketing authorization with the 510(k) clearance from the FDA for BabySat, a prescription use-only pulse oximeter indicated for use in the home environment that measures and displays functional oxygen
32

saturation of arterial hemoglobin and pulse rate and for spot-checking and/or continuous monitoring of well-perfused patients greater than one month old up to 18 months old and weighing between 6 and 30 pounds. In order to market and distribute BabySat or other similar medical devices, we will need to modify certain of our internal business operations so that they comply with medical device requirements and to enable distribution of the product in accordance with the limitations of use described in our marketing authorizations. For example, as the 510(k) clearance for BabySat limits distribution of this product to prescription use-only, we will be unable to utilize the direct-to-consumer model we use to distribute Dream Sock and Owlet Cam (as well as Smart Sock, in certain countries outside of the U.S.). Though we are currently exploring several new distribution channels, including working with durable medical equipment distributors, healthcare institutions, and other healthcare payor and provider channels, we may not be successful in identifying, or implementing with our current resources, an appropriate distribution channel for BabySat. Further, even though we have received FDA clearance for BabySat, we will still need to demonstrate the business and clinical rationale and justifications of this product in order for healthcare institutions and providers to be convinced of the need to prescribe it, and we may not be successful in these efforts.
We are required to maintain authorizations or certifications for our prescription-required BabySat pediatric monitor in the U.S. and for our Dream Sock with Health Notifications in the U.S., EU and UK in order to continue commercializing and selling these products in the named jurisdictions. Failure to maintain such authorizations or certifications on a timely basis, or at all, could severely harm our business.
In June 2023, we received 510(k) clearance from the FDA for BabySat, a prescription use-only pulse oximeter indicated for use in the home environment designed to measure and display functional oxygen saturation of arterial hemoglobin and pulse rate and for spot-checking and/or continuous monitoring of well-perfused patients greater than one month old up to 18 months old and weighing between 6 and 30 pounds. In November 2023, we obtained de novo classification from the FDA for Dream Sock with Health Notifications. As such, both of these products are regulated as medical devices by the FDA, and we must continue to maintain compliance with medical device requirements with respect to the manufacture, sale, marketing, and distribution of these products.
The FDA’s interpretations of its laws and regulations are subject to change. If the FDA changes its policy or concludes that the marketing of any of our products is not in accordance with current policies, regulations or statutory requirements, or if the FDA changes its applicable policies or if changes are introduced to applicable laws or regulations, we may be required to seek clearance or approval or other marketing authorization for these products. If we do not timely comply with updated policies or requirements, we may not be permitted to continue marketing these products until marketing authorization is obtained, or may be the subject of regulatory enforcement actions or recalls. In addition, if safety or effectiveness problems are later identified by the FDA with any of our medical device products, we may need to initiate a product recall.
In March 2024 we received EU MDR certification for Dream Sock in the EU, and in May 2024 we received UKCA MDR certification for Dream Sock in the UK. We are currently marketing and selling Dream Sock in these jurisdictions.
In order to continue to sell medical devices in the EU, products must comply with the general safety and performance requirements of the EU MDR. Continued compliance with these requirements is a prerequisite to be able to affix the European Conformity (“CE”) mark to medical devices, without which they cannot be sold or marketed in the EU. All medical devices placed on the market in the EU must meet the general safety and performance requirements laid down in Annex I to the MDR including the requirement that a medical device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended purpose. Medical devices must be safe and effective and must not compromise the clinical condition or safety of patients, or the safety and health of users and – where applicable – other persons, provided that any risks which may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety, taking into account the generally acknowledged state of the art. To demonstrate compliance with the general safety and performance requirements, We have undergone a conformity assessment in the form of a technical file review conducted by our notified body. Upon completion of the technical file review the notified body issued a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The aforementioned EU rules are generally applicable in the EEA. Non-compliance with the above requirements would also prevent us from continued sales of medical devices in these countries.
Following Brexit, EU laws no longer apply directly in Great Britain. The regulations on medical devices in The UK continue to be based largely on the three EU Directives which preceded the EU MDR, as implemented into national law. However, under the terms of the Protocol on Ireland/Northern Ireland, the EU MDR does apply to Northern Ireland. Consequently, there are currently different regulations in place in the UK as compared to both Northern Ireland and the EU, respectively. Ongoing compliance with both sets of regulatory requirements may result in increased costs for our business.
33

In addition, quality system certifications, both ISO 13485 and MDSAP requirements must be maintained as evidence of ongoing compliance for continued sales of medical devices in the US, EU and UK. We undergo an annual assessment by our notified body of the application of the quality system requirements regarding design and development, product risk profiles and post market surveillance. Failure to maintain the quality system certifications could result in regulatory enforcement action, and/or suspension of sales pending corrective action.
As we expand into international markets, we will be required to obtain and maintain regulatory authorizations, including clearances or approvals, or other certifications in order to commercialize certain of our products in certain international markets. Failure to obtain such regulatory authorizations or certifications in relevant foreign jurisdictions may prevent us from marketing medical device products abroad.
We currently market and intend to continue to market our products and services internationally. We expect certain of our pipeline products to be regulated as medical devices, and we have received communications from certain regulatory authorities inquiring as to the regulatory status of our Smart Sock, and whether such product is regulated as a medical device in such jurisdictions. In these communications, some regulatory authorities have asserted that Smart Sock is a medical device that must comply with medical device requirements in those jurisdictions. See our risk factor titled, “If any governmental authority or notified body were to require marketing authorization or similar certification for any product that we sell for which we have not obtained such marketing authorization or certification, we could be subject to regulatory enforcement actions and/or be required to cease selling or recall the product pending receipt of marketing authorization or similar certification from such other governmental authority or notified body, which can be a lengthy and time-consuming process, harm financial results and have long-term negative effects on our operations.
Risks Related to Our Common Stock and Warrants
Our failure to meet the NYSE’s continued listing requirements could result in a delisting of our common stock.
If we fail to satisfy the NYSE's continued listing requirements, the NYSE may take steps to delist our common stock. For example, in April 2023, we were notified by NYSE that we were not in compliance with Section 802.01B of the NYSE Listed Company Manual as the average global market capitalization of our common stock over a consecutive 30 trading-day period and, at the same time, our last reported stockholders’ equity were each less than $50 million. In May 2023, we submitted a business plan advising the NYSE of the definitive actions we had taken as of the date of that submission and were planning on taking in order to bring us into compliance with NYSE continued listing standards within 18 months of receipt of the NYSE Notification (the “Cure Period”). The plan was accepted by the NYSE in July 2023. We have taken and intend to take further actions to facilitate compliance with the global market capitalization requirement under the NYSE rules. There can be no assurance, however, that we will be able to achieve the actions identified in our plan or that we may otherwise take to regain compliance or that those actions will result in our market capitalization equaling or exceeding $50 million within the Cure Period. Even if we regain compliance, there can be no assurance that we will be able to maintain compliance with these or any other NYSE listing requirements.
Delisting from the NYSE could make trading our common stock more difficult for investors, potentially leading to declines in our share price and liquidity. In addition, without a NYSE market listing, stockholders may have a difficult time getting a quote for the sale or purchase of our common stock, the sale or purchase of our common stock would likely be made more difficult and the trading volume and liquidity of our common stock could decline. Delisting from the NYSE could also result in negative publicity and could also make it more difficult for us to raise additional capital. The absence of such a listing may adversely affect the acceptance of our common stock as currency or the value accorded by other parties. If our common stock is delisted by the NYSE, our common stock may be eligible to trade on an over-the-counter quotation system, such as the OTCQB market, where an investor may find it more difficult to sell our common stock or obtain accurate quotations as to the market value of our common stock. We cannot assure you that our common stock, if delisted from the NYSE, would be eligible to be listed on another national securities exchange or quoted on an over-the counter quotation system.
Additionally, the National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as “covered securities.” If our common stock were no longer listed on the NYSE or any other national exchange, our common stock would not qualify as covered securities under such statute, and we would be subject to regulation in each state in which we offer our securities.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
There were no unregistered sales of equity securities for the three months ended June 30, 2024.
34

Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
(a) None.
(b) None.
(c) During the three months ended June 30, 2024, no directors or "officers" (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted, modified or terminated "Rule 10b5-1 trading arrangements" and/or "non-Rule 10b5-1 trading arrangements" (each as defined in Item 408 of Regulation S-K).
35

Item 6. Exhibits

Exhibit Number | Description | Form | File No. | Exhibit | Filing Date
2.1† | Merger Agreement, dated as of February 15, 2021, by and among the Registrant, Project Olympus Merger Sub, Inc. and Owlet Baby Care Inc. | 8-K | 001-39516 | 2.1 | 2/16/2021
3.1 | Second Amended and Restated Certificate of Incorporation of Owlet, Inc. | 10-K | 001-39516 | 3.1 | 3/8/2024
3.2 | Certificate of Designation of Series A Convertible Preferred Stock of Owlet, Inc. | 8-K | 001-39516 | 3.1 | 2/21/2023
3.3 | Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Owlet, Inc. | 8-K | 001-39516 | 3.1 | 7/7/2023
3.4 | Amended and Restated Bylaws of Owlet, Inc. | S-4 | 333-254888 | 3.4 | 3/31/2021
3.5 | Certificate of Designation of Series B Convertible Preferred Stock of Owlet, Inc. | 8-K | 001-39516 | 3.1 | 3/4/2024
4.1 | Warrant Agreement, dated September 14, 2020, between Sandbridge Acquisition Corp. and Continental Stock Transfer & Trust Company. | 8-K | 001-39516 | 4.1 | 9/18/2020
4.2 | Specimen Warrant Certificate. | S-1 | 333-24832 | 4.4 | 9/1/2020
4.3 | Form of Warrant to Purchase Class A Common Stock in connection with the February 2023 Offering. | 8-K | 001-39516 | 4.1 | 2/21/2023
4.4 | Form of Warrant to Purchase Shares of Class A Common Stock in connection with the February 2024 Offering. | 8-K | 001-39516 | 4.1 | 2/26/2024
4.5 | Amended and Restated Warrant to Purchase Shares of Class A Common Stock, dated February 25, 2024, by and between Owlet, Inc. and Eclipse Early Growth Fund I, L.P. | 8-K | 001-39516 | 4.2 | 2/26/2024
10.1 | Waiver and Fourth Amendment to the Third Amended and Restated Loan and Security Agreement, dated May 10, 2024, between Silicon Valley Bank, as bank lender, and Owlet, Inc. and its subsidiary, Owlet Baby Care, Inc., as borrowers. | 10-Q | 001-39516 | 10.3 | 5/13/2024
31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |  |  |  |
31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |  |  |  |
32.1** | Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |  |  |  |
101.INS* | Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document. |  |  |  |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. |  |  |  |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  |
104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |  |  |  |

*Filed herewith
**Furnished herewith.
†The annexes, schedules, and certain exhibits to this Exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant hereby agrees to furnish supplementally a copy of any omitted annex, schedule or exhibit to the SEC upon request.
#Certain portions of this exhibit (indicated by “[***]”) have been omitted pursuant to Regulation S-K, Item 601(b)(10).
36

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| Company Name
Date: August 14, 2024 | By: | /s/ Kurt Workman
| Name: | Kurt Workman
| Title: | Chief Executive Officer
|  | (Principal Executive Officer)
Date: August 14, 2024 | By: | /s/ Amanda Crawford
| Name: | Amanda Crawford
| Title: | Chief Financial Officer
|  | (Principal Financial Officer and Principal Accounting Officer)

37